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Pulmonary carcinoid (PC) tumors are rare neuroendocrine lung neoplasms 
that have in general an indolent clinical course. Based on morphology, PC 
tumors are categorized into typical carcinoid (TC) tumors and atypical 
carcinoid (AC) tumors. The primary treatment is surgery, while there is no 
consensus on the treatment of metastatic disease. Thus, effective and more 
targeted therapies are needed for the PC patients who are inoperable or not 
curable with surgery alone. While histologic subtype and stage are important 
prognostic factors, other predictive and prognostic factors or biomarkers are 
urgently needed for individualized treatment and patient-tailored surveillance 
protocols. The main aim of this thesis was to find tissue-based biomarkers in 
PC tumors by utilizing the Finnish hospital-integrated biobanks as a source of 
the study material. 
The nationwide study cohort consisted of 224 PC tumor patients operated 
on between 1990 and 2013 in Finnish university or central hospitals. Tissue 
specimens were re-evaluated according to the latest World Health 
Organization classification criteria, processed into tissue microarray format 
and labeled immunohistochemically against 16 different proteins. Extensive 
clinical information on the patients coupled with survival and cause of death 
data were retrieved from the biobanks. PC tumor and lung cancer incidence 
data between 1990 and 2016 were applied for from the Finnish Cancer 
Registry (FCR). 
According to the FCR data, PC tumors represent approximately 1% of all 
diagnosed lung cancers in Finland. Between 1990 and 2016, lung cancer 
incidence in Finland decreased from 25.9 to 20.2 per 100 000 persons, while 
PC tumor incidence doubled from 0.2 to 0.4 per 100 000 persons. The rise is 
due, at least in part, to increased use of imaging techniques and improved 
awareness among clinicians.  
During the re-evaluation of the tumors, 21% of the original biobank 
database diagnoses changed. Eighty-one per cent (n=182) of the tumors were 
classified as TCs and 19% (n=42) as ACs. The median tumor size was 2.0 cm, 
with no difference between TC and AC tumors. Hilar/mediastinal lymph node 
involvement at the time of primary surgery was more common in AC patients 
than in TC patients (21% vs 7%, P=0.030). Similarly, metastatic disease or 
recurrent tumor were more often observed in AC patients than in TC patients 
(21% vs 6%, P=0.001). 
The median follow-up time of the patients was 11.4 years (mean 12.7 years, 






and 33 (15%) died from unrelated causes. The 10-year disease-specific survival 
(DSS) rate was 98% for TC patients and 81% for AC patients. 
Five clinicopathological factors were recognized to be associated with the 
risk of disease-specific mortality. These were age over 56 at diagnosis, tumor 
size over 2.5 cm, atypical subtype, hilar/mediastinal lymph node involvement 
at diagnosis, and presence of metastatic disease. Similarly, lack of 
somatostatin receptor (SSTR) 1 expression and presence of SSTR3 expression 
as well as a Ki-67 proliferation index over 2.5% were identified as risk factors 
for shorter DSS. In addition, lack of SSTR2 expression and presence of SSTR4 
expression was associated with a risk of shorter DSS in AC patients. 
Metastasized PC tumors expressed significantly more SSTR4 and 
programmed death ligand 1 (PD-L1) than non-metastasized tumors. In 
addition, lack of SSTR1 or SSTR2 expression was associated with metastatic 
disease. None of the analyzed biomarkers were able to separate between TC 
and AC tumor. 
Based on biobank registry data, Finnish hospital-integrated biobanks were 
able to identify 88% of the histologically verified PC tumor patients registered 
by the FCR. However, they were only able to deliver 63% of the tumor samples 
because samples were missing in the archives or they were too scarce. The 
most challenging part of the biobanks’ workflow was collecting the clinical 
data. 
In conclusion, PCs are rare neoplasms. When resected, the long-term 
survival is favorable. The SSTR expression profile and PD-L1 expression are 
associated with the tumor’s metastatic potential and patient outcome, offering 
the possibility for individualized prognosis estimation and surveillance 
protocol. Since the SSTRs and the PD-L1 are therapy targets, their expression 
provides also predictive value. The Finnish hospital-integrated biobanks offer 
excellent opportunities for tissue-based research. However, more medical 
knowledge needs to be included in the sample and data acquisition process. In 
addition, re-evaluation of the biobank tissue samples collected over decades is 
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Lung cancer is the most common cause of cancer-related deaths in industrial 
countries. The most common histologic types are adenocarcinoma, squamous 
cell carcinoma, small-cell carcinoma, and large-cell carcinoma (Kumar et al. 
2018). 
Pulmonary neuroendocrine tumors (NETs) account for approximately 20% 
of all lung malignancies. They are a heterogeneous group of neoplasms with 
variable clinical outcomes ranging from low- and intermediate-grade 
carcinoid tumors to high-grade large-cell neuroendocrine carcinoma (LCNEC) 
and small-cell carcinoma (Travis et al. 2015a). 
Pulmonary carcinoid (PC) tumors are rare neoplasms representing 
approximately 1% of all lung cancers, with an incidence ranging from 0.5 to 1.5 
persons per 100 000 population per year (Dasari et al. 2017; Korse et al. 2013). 
Based on histologic criteria, they are divided into two subcategories: low-grade 
typical carcinoid (TC) tumor and intermediate-grade atypical carcinoid (AC) 
tumor (Travis et al. 2015a).  
PC tumor patients have in general a good prognosis, especially when 
resected, with a 5-year survival rate of 89% (Kneuertz et al. 2018). However, 
both TC and AC are malignant tumors with the potential to metastasize. 
Clinically, AC tumors are more aggressive as one fourth of them develop into 
metastatic disease. Of TC tumors, only 4% metastasize (Wolin 2017).  
The incidence of PC tumors is increasing worldwide (Yao et al. 2008). At 
the same time, management of PC tumor patients remains challenging since 
there is a paucity of biomarkers that could facilitate diagnosis and surveillance. 
Because of the rarity, prospective collection of a sufficient number of tumor 
tissue samples in order to discover and validate new biomarkers is difficult and 
time-consuming. Moreover, long-term follow-up of the patients is needed 
since PC tumors are known to develop distant metastases many years after 
resection of the primary tumor (Gustafsson 2008a).  
In Finland, approximately 30 PC tumors are diagnosed annually. Most of 
the PC tumor patients are treated in university or central hospitals where the 
Finnish hospital-integrated biobanks are located. These biobanks contain 
millions of tissue samples from nearly 3 million Finns and are thus a valuable 
source of study material (BBMRI.fi 2019). 
In this study, Finnish hospital-integrated biobanks were utilized to collect 
a nationwide PC tumor patient series. This series included tissue samples from 
each patient in a tissue microarray (TMA) format, coupled with extensive 
clinical and outcome data. In this PC tumor tissue material, the expression of 





new diagnostic, predictive, or prognostic biomarkers, or target molecules, for 
precision medicine. Moreover, the performance of the Finnish hospital-





2 REVIEW OF THE LITERATURE 
2.1 DIFFUSE NEUROENDOCRINE SYSTEM AND 
NEUROENDOCRINE TUMORS 
The diffuse neuroendocrine system consists of single or clustered 
neuroendocrine cells found mainly in the digestive and respiratory systems 
but also in other locations such as the urogenital tract, skin, and thyroid gland 
(Montuenga et al. 2003).  Neuroendocrine cells secrete hormones but they do 
not form discrete endocrine glands. They have similar cytological and 
biochemical traits to neural cells, such as the presence of small, dense 
secretory granules and characteristic surface membrane markers (Montuenga 
et al. 2003). 
Although the precise function of the diffuse neuroendocrine system 
remains unclear, it is considered to play a role in regulating secretion, 
absorption, and motility. Neuroendocrine cells synthesize specific peptides 
and amines, which are released via secretory granules and exocytosis to 
regulate biological processes in an autocrine, paracrine, and endocrine fashion 
(Modlin et al. 2010; Montuenga et al. 2003).   
Neuroendocrine neoplasms arising from neuroendocrine cells are 
classified into foregut, midgut, and hindgut tumors according to the 
embryonic divisions of the digestive tract (Figure 1). Neuroendocrine 
neoplasms are rare, comprising approximately 2% of all malignancies (Dasari 
et al. 2017). Their incidence is increasing in great part due to more sensitive 
diagnostic tools and general awareness among clinicians (Dasari et al. 2017; 
Gustafsson et al. 2008b). The most common primary tumor sites are the 
gastrointestinal tract (62–67%) and lungs (22–27%) (Oronsky et al. 2017).  
Neuroendocrine neoplasms are generally categorized by morphological 
features and proliferation rate as low-grade indolent NETs and high-grade 
aggressive neuroendocrine carcinomas (Oronsky et al. 2017). They are 
characterized by their ability to synthesize, store, and secrete peptides and 
amines that can cause hormonal syndromes (Oronsky et al. 2017). More than 
half of NETs are metastatic at diagnosis due to lack of symptoms in the early 





2.2 NEUROENDOCRINE SYSTEM OF THE LUNGS 
The lungs are paired intrathoracic organs that are divided into lobes (Corrin & 
Nicholson 2011). The main components of the lung parenchyma are the 
bronchi and bronchioles (airways) and the alveoli. Type I and type II 
pneumocytes line the alveoli while the main cell types of the 
bronchial/bronchiolar epithelium are ciliated cells, secreting cells (goblet cells, 
serous cells, and Clara cells), basal cells, and neuroendocrine cells (Rosai & 
Ackerman 2011).  
Pulmonary neuroendocrine cells (PNEC), also known as Kulchitsky-type 
cells, Feyrter cells, and amine precursor uptake and decarboxylation (APUD) 
cells, belong to the diffuse neuroendocrine system distributed throughout 
multiple organs in the body (Linnoila 2006; Montuenga et al. 2003). Although 
PNECs resemble neural cells morphologically, they are of endodermal origin 
(Gustafsson et al. 2008a). The PNEC system consists of airway epithelial cells, 
which are associated with nerve fibres and display endocrine and paracrine 
secretory mechanisms (Linnoila 2006; Van Lommel et al. 1999). PNECs are 
typically tall and basally located, possessing apical microvilli projecting into 
the airway lumen (Gustafsson et al. 2008a). They are distributed throughout 
the airways from the main bronchi to the bronchioles but are only rarely found 
Figure 1. Neuroendocrine neoplasms divided by the site of origin (from Oronsky 
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in the terminal bronchioles and alveoli (Corrin & Nicholson 2011; Gustafsson 
et al. 2008a). 
During lung development, PNECs are the first cell type to form and 
differentiate within the airway epithelium (Gustafsson et al. 2008a). The 
number of PNECs increases as birth approaches and the peak is reached 
during the neonatal period (Gustafsson et al. 2008a). In the healthy adult lung, 
PNECs are scattered with approximately one PNEC per 2500 epithelial cells 
(Gosney et al. 1988). PNECs exist as isolated cells but can also form clusters 
called neuroepithelial bodies (NEBs) (Van Lommel et al. 1999). In the normal 
adult lung, the majority of PNECs are solitary while in infants and neonates 
NEBs are more common (Linnoila 2006).  
The main function of PNECs is to act as local modulators of lung growth 
and differentiation during lung organogenesis (Corrin & Nicholson 2011). 
Thereafter, they are thought to have a role in pulmonary regeneration and 
repair as well as acting as airway chemoreceptors (Corrin & Nicholson 2011; 
Gustafsson et al. 2008a; Linnoila 2006; Van Lommel et al. 1999). In particular, 
NEBs are known to monitor the concentration of airway gases and to sense 
hypoxia (Figure 2) (Linnoila 2006; Van  Lommel et al. 1999). In addition, 
PNECs synthesize and secrete for example serotonin, calcitonin, 
adrenocorticotropic hormone (ACTH), and gastrin-releasing peptide (Van 
Lommel et al. 1999). The precise effect of PNEC secretions is not definitely 
known but they can enter the general circulation via the airway mucosal 
capillaries and pulmonary venous blood and act as typical hormones (Van 
Lommel et al. 1999). 
Even if PNECs are only a minor component of the lung epithelium, 
approximately one fifth of human lung cancers display features of 
neuroendocrine differentiation (Travis et al. 2015a). Clinically, the most 
relevant pulmonary NET is small-cell carcinoma, which accounts for 
approximately 15% of all lung cancers. Other tumors include large-cell 





















Figure 2. Schematic representation of the role for neuroepithelial bodies (NEBs) as airway 
sensors. 
(A) NEB initiated neural regulation modulates pulmonary homeostatic processes including 
airway tone, pulmonary circulation, and control of breathing. Pulmonary vagal afferent fibers 
(1) pass to the brainstem, and dorsal root ganglionic (DRG) afferent fibers (2) communicate 
with the spinal cord. Reflex response signals are transmitted to the lungs via parasympathetic 
(3) and sympathetic nerve fibers, as well as to the diaphragm via the phrenic nerve (4). 
(B) Magnified schematic diagram demonstrating the mechanism of hypoxia-induced 
degranulation of NEBs (green). The released dense core vesicles (red) contain signal 
substances including serotonin, calcitonin gene-related peptide, bombesin, calcitonin, 
enkephalin, somatostatin, and cholecystokinin, which activate vagal and DRG afferent 
neurons as well as adjacent epithelial, vascular, or smooth muscle cells. DRGs in turn activate 
intrinsic efferent neurons facilitating feedback signaling to the NEBs. A single pulmonary 
neuroendocrine cell (PNEC) (yellow) with basal extension provides paracrine influence on 
adjacent mucosal cells. 
From Gustafsson et al. 2008a, p. 8, Fig. 3. Reproduced with the original legend with the 
permission of John Wiley and Sons. 
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2.3 PRIMARY TUMORS OF THE LUNG 
Approximately 95% of primary lung neoplasms are carcinomas. The 
remaining 5% represent a miscellaneous group of tumors including carcinoids, 
mesenchymal malignancies, lymphomas, and benign lesions (Kumar et al. 
2018).  
Lung cancer is the leading cause of cancer deaths worldwide. As tobacco 
smoking is the most common cause of lung cancer, the incidence of lung 
cancer mirrors closely changes in smoking habits. Other known risk factors 
include radon in the indoor environment and mines, outdoor air pollution, and 
occupational agents such as asbestos (Travis et al. 2015a). Approximately 60% 
of lung cancers are incurable when first detected due to extensive local spread 
and distant metastases, and 5-year survival is less than 15% (Rosai & 
Ackerman 2011). 
Traditionally, lung cancers are classified into two broad groups: small-cell 
lung cancer (SCLC), in other words small-cell carcinoma, and non-small-cell 
lung cancer (NSCLC). The 2015 World Health Organization (WHO) 
classification divides epithelial lung cancers further into 12 main categories 
(Table 1) (Travis et al. 2015a).  
 
Table 1. Histologic classification of malignant epithelial lung tumors 
according to the 2015 World Health Organization classification. 
Adenocarcinoma 
 Subtypes: lepidic, acinar, papillary, micropapillary, solid, 
invasive mucinous, colloid, fetal, enteric, minimally invasive 
Squamous cell carcinoma 
 Subtypes: keratinizing, non-keratinizing, basaloid 
Neuroendocrine tumors 
 Subtypes: small-cell carcinoma, large-cell neuroendocrine 








Other and unclassified carcinomas 
Salivary-gland type tumors 
 Subtypes: mucoepidermoid carcinoma, adenoid cystic 




Adenocarcinoma is the most common lung cancer type followed by squamous 





cancers are separated based on morphology and immunohistochemical 
staining pattern (Table 2). Of note, none of the immunohistochemical stains 
are 100% specific for any lung cancer subtype, and also mixed tumors exist 
(Travis et al. 2015a).  
 
 
Table 2. Immunohistochemical profile of the major lung cancer types. Modified from Rosai & 
Ackerman 2011 and Travis et al. 2015a. Chrom A, chromogranin A; CK, cytokeratin; NA, not 
applicable; TTF-1, thyroid transcription factor-1. 
 
 
TTF-1 CD56 Napsin A CK5/6 p40 Chrom A Ki-67 
Adenocarcinoma + − + − − − NA 
Squamous cell 
carcinoma − − − + + − NA 
Small-cell 
carcinoma + + − − − + >50% 
 
2.4 PULMONARY CARCINOID TUMORS 
PC tumors are neuroendocrine epithelial malignancies that are divided into 
two subcategories: typical carcinoid (TC) tumor and atypical carcinoid (AC) 
tumor (Travis et al. 2015a). According to the current WHO classification of 
lung tumors, PCs belong to pulmonary NETs together with small-cell 












Other and unclassified carcinomas
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tumors are intermediate-grade malignancies, while small-cell carcinoma and 
LCNEC are considered high-grade malignancies. PCs are only distantly related 
to the high-grade carcinomas since these two groups of tumors represent 
major epidemiological, clinical, histologic, genetic, and prognostic differences. 
 
2.4.1 EPIDEMIOLOGY AND INCIDENCE 
 
PCs are rare tumors that account for approximately 1% of all lung cancers 
(Naalsund et al. 2011; Skuladottir et al. 2002). Globally, the annual age-
standardized incidence for PC tumors ranges from <0.5 per 100 000 persons 
to 1.5 per 100 000 persons (Boyar Cetinkaya et al. 2017; Dasari et al. 2017; 
Hallet et al. 2015; Korse et al. 2013; Luke et al. 2010). The majority of PC 
tumors are TC tumors, while AC tumors account for just 10–30% (Cao et al. 
2011; Cusumano et al. 2017; Papaxoinis et al. 2018; Rea et al. 2007). The 
incidence of PC tumors has increased during recent decades (Boyar Cetinkaya 
et al. 2017; Modlin et al. 2003; Yao et al. 2008). The rise has been ascribed at 
least in part to the increased use of imaging techniques, improved diagnostic 
protocols, and increased awareness among clinicians (Gustafsson et al. 
2008b). 
According to large registry-based studies, approximately two thirds of the 
PC tumors occur in females (Filosso et al. 2015; Hobbins et al. 2016). However, 
when comparing only AC tumors, both genders are equally represented 
(Beasley et al. 2000; Daddi et al. 2014). The mean age at PC tumor 
presentation is around 50 years, but they can also occur in children (Cao et al. 
2011; Geramizadeh et al. 2013). In fact, PC tumor is the most common primary 
pulmonary tumor of childhood (Rojas et al. 2015).  
 
2.4.2 ETIOLOGY AND RISK FACTORS 
 
The cell of origin as well as the etiology of the PC tumor are largely unknown. 
Historically, PC tumors were thought to arise from PNECs, but the current 
WHO classification of lung tumors states that the cell of origin is unknown 
(Travis et al. 2015a). However, the same classification defines diffuse 
idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) as a 
preinvasive lesion of a subset of PC tumors. DIPNECH is characterized by a 
proliferation of neuroendocrine cells in small bronchi and bronchioles 
confined to the airway mucosa. When invading beyond the confines of the 
airway and becoming extraluminal, the term tumorlet is applied. If the 
diameter of the tumorlet is at least 0.5 cm, the tumor is arbitrarily designated 
as a PC tumor. PC tumors associated with DIPNECH are almost always TC 





even if the literature describes several PC tumors to occur together with 
DIPNECH, there is limited evidence on patients whose carcinoid tumor 
developed subsequently to an initial diagnosis of DIPNECH (Aubry et al. 
2007).  
Most PCs are assumed to be sporadic. The only evidence of heritable 
etiology is the presence of multiple endocrine neoplasia (MEN) type 1 
syndrome due to MEN1 germ-line mutation (Thevenon et al. 2015). It is 
estimated that 5–13% of MEN1 patients develop a PC tumor (de Laat et al. 
2014; Sachithanandan et al. 2005). In addition, unassociated with MEN1, 
familial PC tumors have been reported (Oliveira et al. 2001). 
In general, PCs have not been linked to exposure to carcinogens such as 
asbestos or tobacco smoke (Bini et al. 2008; El Jamal et al. 2000; Schrevens 
et al. 2004). In a series of 28 patients, asbestos exposure was identified more 
often in PC tumor patients than in age and gender matched controls having 
other types of lung cancer (Clin et al. 2012). Moreover, a possible relationship 
between AC tumor and smoking has been reported (Fink et al. 2001).  
 
2.4.3 GENETIC ALTERATIONS AND PATHOGENESIS 
 
Based on next-generation sequencing studies, PC tumors are characterized by 
a low somatic mutation rate (0.4–1.6 per million basepairs) with chromatin 
remodeling being the most frequently mutated pathway (Fernandez-Cuesta et 
al. 2014; Simbolo et al. 2017; Yao et al. 2019). Chromatin remodeling is a 
process that controls gene expression in cells by opening or closing chromatin 
structure to allow or prevent a transcriptional regulatory protein to bind to 
DNA. Genes involved in chromatin remodeling can be classified into two 
categories: covalent histone-modifying (acetylation, methylation, 
phosphorylation, and ubiquination) complexes and adenosine triphosphate-
dependent chromatin modeling complexes (e.g. SWI/SNF) (Devlin 2010).  
Altogether, mutations in chromatin remodeling genes have been reported 
in 35–51% of PC tumors (Fernandez-Cuesta et al. 2014; Laddha et al. 2019; 
Simbolo et al. 2017). MEN1 mutations are seen in 5–18% of PCs, usually 
accompanied by loss of heterozygosity (Fernandez-Cuesta et al. 2014; Laddha 
et al. 2019; Simbolo et al. 2017; Yao et al. 2019). In addition, mutations in 
genes involved in covalent histone modifications have been found in 14–40% 
of the PC tumors, whereas mutations in the SWI/SNF complex are present in 
9–22% of the tumors (Table 3). Another recurrently affected pathway with, for 
example, single STAG1, NIPBL, DICER, ERCC6L, and MED24 mutations is 
sister-chromatid cohesion during cell cycle progression (Fernandez-Cuesta et 
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Table 3. The most frequently mutated pathways and genes in pulmonary carcinoid tumors. 





  n        (%) 
Authors 
     
Tumor 
suppressor 
MEN1 74 4 (5) Fernandez-Cuesta et al. 2014 
 88 10 (11) Simbolo et al. 2017 
 34 6 (18) Yao et al. 2019 
 30 4 (13) Laddha et al. 2019 
TP53 74 1 (1) Fernandez-Cuesta et al. 2014 
 88 9 (10) Simbolo et al. 2017 
RB1 74 1 (1) Fernandez-Cuesta et al. 2014 
 88 2 (2) Simbolo et al. 2017 
      
      
SWI/SNF 
complex 
ARID1A 74 3 (4) Fernandez-Cuesta et al. 2014 
 88 5 (6) Simbolo et al. 2017 
 30 3 (10) Laddha et al. 2019 
ARID1B 88 1 (1) Laddha et al. 2019 
ARID2 74 1 (1) Fernandez-Cuesta et al. 2014 
 88 2 (2) Simbolo et al. 2017 
SMARCA1 74 1 (1) Fernandez-Cuesta et al. 2014 
SMARCA2 74 1 (1) Fernandez-Cuesta et al. 2014 
SMARCA4 74 1 (1) Fernandez-Cuesta et al. 2014 
 88 3 (3) Simbolo et al. 2017 
 30 1 (3) Laddha et al. 2019 
SMARCC2 74 1 (1) Fernandez-Cuesta et al. 2014 
SMARCB1 74 1 (1) Fernandez-Cuesta et al. 2014 
BCL11A 74 1 (1) Fernandez-Cuesta et al. 2014 
      




KMT2A 88 1 (1) Simbolo et al. 2017 
 30 1 (1) Laddha et al. 2019 
KMT2C 88 7 (8) Simbolo et al. 2017 
 30 2 (3) Laddha et al. 2019 
KMT2D 88 4 (5) Simbolo et al. 2017 
 30 1 (1) Laddha et al. 2019 
SETD1B 74 1 (1) Fernandez-Cuesta et al. 2014 
SETDB1 74 2 (3) Fernandez-Cuesta et al. 2014 
NSD1 74 1 (1) Fernandez-Cuesta et al. 2014 
      
      
Other EIF1AX 74 4 (5) Fernandez-Cuesta et al. 2014 
PSIP1 74 2 (3) Fernandez-Cuesta et al. 2014 
PCLO 88 4 (5) Simbolo et al. 2017 
NOTCH2 88 4 (5) Simbolo et al. 2017 
DSCAML1 88 4 (5) Simbolo et al. 2017 
 
 
PCs display a low median chromosomal instability score (0.19) (Yao et al. 
2019). In a large structural copy number alteration (CNA) analysis, PC tumors 
rarely showed gains or losses of chromosomes (Laddha et al. 2019; Simbolo et 
al. 2017). The most frequently observed chromosomal alteration is the deletion 
of 11q (Swarts et al. 2011). It is less frequently lost in TCs than ACs, indicating 
that it could represent a marker of tumor progression rather than tumor 





both copies of RB1 (TCs, 13% (n=3) and ACs, 14% (n=2)) and TP53 (TCs 9% 
(n=2), ACs 7% (n=1)). Gains have been observed for TERT, MST2, SDHA, 
RICTOR, and PIK3CA (TCs 9% (n=2), ACs 14% (n=2)). The average number 
of genes affected by CNA is 1.3 for TCs and 2.0 for ACs (Simbolo et al. 2017).  
In contrast to small-cell carcinoma and LCNEC, mutations in TP53 and 
RB1 are rare (Table 3). Thus, inactivation of chromatin remodeling genes 
seems to be enough to drive the early steps in the pathogenesis of the PC tumor. 
However, single hypermutated PC tumors or tumors with chromothripsis have 
also been reported as well as a TC tumor with BRAF, SMAD4, PIK3CA, and 
KRAS mutations (Armengol et al. 2015; Fernandez-Cuesta et al. 2014; Simbolo 
et al. 2017). It has also been shown that ACs share molecular features of both 
low-grade TC and high-grade small-cell carcinoma and LCNEC (Simbolo et al. 
2017, 2019). Recently, a proof-of-concept study suggested that pre-existing TC 
or AC can further progress to high-grade neuroendocrine carcinoma (Pelosi et 
al. 2018). Similarly, the group of supra-carcinoids that comprises tumors with 
carcinoid-like morphology coupled with molecular and clinical features of the 
LCNEC was recently unveiled to support the molecular link between PC 
tumors and high-grade NETs (Alcala et al. 2019). 
 
2.4.4 SOMATOSTATIN RECEPTOR EXPRESSION 
 
Somatostatin, a polypeptide hormone distributed widely throughout the 
central nervous system and peripheral tissues, has a broad range of biological 
actions. It regulates neurotransmission and secretion, and inhibits the release 
of several hormones (e.g. growth hormone, prolactin, thyroid-stimulating 
hormone, and gastrointestinal hormones) (Gunther et al. 2018; 
Theodoropoulou & Stalla 2013). Somatostatin is also involved in antitumor 
activity via inducing cell cycle arrest and/or apoptosis, and by inhibiting tumor 
angiogenesis and the production of factors supporting tumor growth 
(Theodoropoulou & Stalla 2013). 
The actions of somatostatin are mediated via five somatostatin receptors 
(SSTR), named SSTR1–5 (Gunther et al. 2018). These transmembrane 
receptors are expressed in several normal human tissues, but their expression 
is highly increased in NETs (Gunther et al. 2018; Reubi & Schonbrunn 2013). 
This overexpression provides a molecular basis for both tumor imaging and 
treatment with somatostatin analogues (SSAs).  
Reports on the SSTR expression on protein level in PC tumors are available 
but they describe fluctuating expression levels. However, SSTR2 seems to be 
the most commonly expressed SSTR (in 43-96% of PC tumors), followed by 
SSTR1 (63-83%) and SSTR5 (0-71%) (Kaemmerer et al. 2015; Kanakis et al. 
2015; Righi et al. 2010; Tsuta et al. 2012). SSTR4 is the least studied receptor 
with the lowest reported expression level (4%) (Tsuta et al. 2012).  
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Synthetic analogues of somatostatin that are approved for the treatment of 
NET patients include octreotide and lanreotide (Caplin et al. 2015). Both have 
similar effect on tumor cells and bind preferably to SSTR2 and with lower 
affinity to SSTR5. In addition, octreotide has affinity for SSTR3 (Reubi & 





Figure 4. Antiproliferative effect of somatostatin analogue on tumor cells. From Theodoro-
poulou & Stalla 2013, p. 232, Fig.1. Reproduced with the permission of Elsevier. 
 
 
A third analogue, pasireotide, currently approved for the treatment of 
Cushing’s syndrome and acromegaly, is under clinical trials for the evaluation 
of safety and efficacy in NET patients (Vitale et al. 2018). It binds with the 





Schonbrunn 2013). Multireceptor targeting analogues KE108 and somatoprim 
are under development (Reubi & Schonbrunn 2013). 
 
2.4.5 CLINICAL MANIFESTATION 
 
PC tumors can be found from the trachea to the bronchioles (Rosai & 
Ackerman 2011). They are traditionally divided into central and peripheral 
tumors based on their location in the bronchial tree. The distribution between 
centrally and peripherally located tumors is almost even: 48–61% versus 39–
52% (Canizares et al. 2014; Daddi et al. 2014; Filosso et al. 2015; Papaxoinis 
et al. 2018). 
Peripherally located PC tumors are usually asymptomatic and discovered 
in a radiological examination carried out for other reasons, whereas centrally 
located tumors often present with respiratory symptoms (Dincer et al. 2015). 
The most frequent symptoms include recurrent chest infections, cough, 
hemoptysis, dyspnea, chest pain, and wheezing (Caplin et al. 2015; Öberg et al. 
2012). Patients with a PC tumor can also present with symptoms resulting 
from overproduction of hormones or active amines (Caplin et al. 2015; Phan 
et al. 2010). Carcinoid syndrome due to overproduction of serotonin and other 
bioactive amines is observed in 2–8% of PC tumor patients, most often related 
to liver metastasis (Caplin et al. 2015; Halperin et al. 2017). The symptoms 
include cutaneous flushing, diarrhea, wheezing, and fibrotic valvular heart 
disease (Halperin et al. 2017). Moreover, Cushing’s syndrome from the 
overproduction of ACTH as well as acromegaly due to overproduction of 
growth hormone-releasing hormone (GHRH) or insulin-like growth factor 1 
(IGF-1) are seen in a small subset of patients (1–6%) (Caplin et al. 2015; 




Patients suspected of having a PC tumor based on clinical symptoms or chest 
X-ray should undergo biochemical assessment, radiological imaging, and 
confirmation of the diagnosis by histologic evaluation. Also, specific gene 





The biochemical tests include single PNEC secretory products like plasma 
chromogranin A, plasma neuron-specific enolase, and urine or serum 5-
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hydroxyindoleacetic acid measurements (Caplin et al. 2015; Phan et al. 2010; 
Öberg et al. 2012). If symptoms characteristic of syndromes are present, 
indicating that the tumor is functional, serum cortisol, 24 h urine free cortisol, 
plasma ACTH, serum GHRH, and serum IGF-1 are recommended to be 
measured (Caplin et al. 2015; Öberg et al. 2012). However, none of these 





Radiological imaging is performed to determine the primary tumor site as well 
as the extent of disease. The gold standard is a contrast computed tomography 
(CT) scan while magnetic resonance imaging (MRI) helps to detect bone or 
liver metastasis (Caplin et al. 2015; Maxwell & Howe 2015).  
As both CT and MRI imaging are often nonspecific for PC tumors, and since 
the majority of PC tumors express SSTRs, functional imaging with nuclear 
medicine can be utilized (Caplin et al. 2015; Maxwell & Howe 2015). The most 
common method is somatostatin receptor scintigraphy (SRS, OctreoScan) 
with radiolabeled SSA (111Indium-labeled octreotide) in conjunction with 
single photon emission computed tomography and CT (Maxwell & Howe 
2015). Whenever available, 68Gallium-DOTA-peptide positron emission 
tomography (PET) scanning is preferable to SRS since it offers higher binding 
affinity to SSTRs and better resolution leading to higher sensitivity and 
specificity (Gosain et al. 2018; Maxwell & Howe 2015). In addition, 18Fluorine-
fluorodeoxyglucose PET (FDG-PET) is used for detecting PC tumors, but it is 
less sensitive since PC tumors tend to be metabolically relatively inactive 





If the tumor is centrally located, bronchoscopy with a biopsy specimen is 
indicated (Caplin et al. 2015; Dixon et al. 2016). In addition, fine needle 
aspiration cytology offers a low invasive technique for diagnosing a PC tumor 
(Biancosino et al. 2016). In both situations, it should be emphasized that 
differentiating between TC and AC from these sample types is difficult due to 
a low amount of tumor cells (Caplin et al. 2015).  
As PC tumors are frequently covered by intact mucosa and do not exfoliate 
cells in sputum, it is challenging to diagnose a PC from sputum, bronchial 
washing, or even bronchial brushing (Aron et al. 2004; Dixon et al. 2016; 
Reynolds et al. 2014). Thus, histologic specimen remains the gold standard for 








One of the newest diagnostic tests for NETs is a polymerase chain reaction-
based blood test called NETest. It measures a panel of 51 neuroendocrine-
specific circulating mRNAs from peripheral blood as a biomarker for NET 
disease (Modlin et al. 2013). Its diagnostic sensitivity (84–93%), specificity 
(89–100%), and accuracy (92%) for detecting pulmonary NETs has been 
proved (Filosso et al. 2018; Malczewska et al. 2019a). Moreover, NETest can 
discriminate between metastatic PC tumor and localized disease (Malczewska 
et al. 2019a). However, a positive NETest does not differentiate between TC 
and AC or even between small-cell carcinoma, LCNEC, and PC tumors but only 
suggests the tumor to have a neuroendocrine phenotype (Malczewska et al. 
2019a). 
 
2.4.7 GROSS APPEARANCE AND HISTOPATHOLOGY 
 
PC tumors usually present as a slow-growing, solitary polypoid mass within a 
major bronchus (Rosai & Ackerman 2011). The tumor is well-circumscribed, 
round to ovoid, and covered by bronchial mucosa (Figure 5A). The cut-surface 
is greyish-yellow and very well vascularized (Rosai & Ackerman 2011). 
Nodular neuroendocrine proliferations smaller than 0.5 cm in diameter are 
classified as tumorlets; PC tumors range from 0.5 to 9.5 cm (Travis et al. 
2015a).  
Microscopically, PC tumor cells are small and uniform and have central 
nuclei with sparse or no mitotic activity. They have a moderate amount of 
finely granular cytoplasm (Rosai & Ackerman 2011). PC tumors show most 
often organoid and trabecular patterns, but a rosette formation, papillary 
growth, pseudoglandular growth, and follicular growth may also be seen 
(Figure 5B) (Travis et al. 2015a). Spindle cell growth is commonly observed in 
peripheral tumors as well as a mix of different patterns within an individual 
tumor. Vascularity is pronounced and the stroma can be heavily sclerotic or 
hyalinized exhibiting focal calcification or ossification (Rosai & Ackerman 
2011).  
In 1972, Arrigoni et al. defined AC tumor as a carcinoid tumor with 
increased mitotic activity (≥1 mitotic figure per 1–2 high-power fields), 
necrosis, nuclear pleomorphism, hyperchromatism, and an abnormal nuclear 
to cytoplasmic ratio coupled with areas of cellular disorganization (Arrigoni et 
al. 1972). In 1998, Travis et al. proposed new criteria for the classification of 
neuroendocrine lung tumors (Travis et al. 1998). They were implemented in 
the WHO classification from 1999 and remained the same in the classification 
from 2004 (Beasley et al. 2005). The next and current WHO classification is 
from 2015. The major difference between versions 2004 and 2015 is 
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Figure 5. (A) Gross image of a carcinoid tumor showing a well-circumscribed tumor nodule 
split in two parts (photograph by Mikko Mäyränpää). (B) Typical carcinoid (TC) tumor with 
organoid arrangement. (C) Atypical carcinoid tumor showing a mitosis (arrow). (D) Strong 
cytoplasmic chromogranin A staining and (E) synaptophysin staining in a TC tumor. (F). Ki-67 
proliferation index of 1% in a TC tumor.  Images B–F were obtained from digitized slides with 
the CaseViewer software. 
 
According to the current classification, a TC tumor is a low-grade and an AC 





necrosis and have less than 2 mitosis per 2 mm2. In contrast, AC tumors 
display 2–10 mitoses per 2 mm2 and/or foci of necrosis (Figure 5C). Both 
tumors have to be ≥0.5 cm in diameter; smaller tumors are recognized as 
tumorlets (Travis et al. 2015a). 
The mitotic rate should be counted in the area of the highest mitotic activity 
per 2 mm2, rather than from 10 high-power fields. Tumors with mitotic activity 
near the cut-offs 2 and 10 mitoses per 2 mm2, should be counted from at least 
three sets of 2 mm2, and the mean value should be used to determine the 
mitotic count (Travis et al. 2015a).  
 
2.4.8 IMMUNOHISTOCHEMISTRY AND DIFFERENTIAL DIAGNOSIS 
 
Immunohistochemical labeling with neuroendocrine (e.g. chromogranin A, 
synaptophysin (Figure 5D–E), and neural cell adhesion molecule CD56) and 
epithelial markers (e.g. pan-cytokeratin) is recommended to confirm 
neuroendocrine origin and epithelial differentiation, especially if the tissue 
material is scarce (Caplin et al. 2015; Travis et al. 2015a, 2015b). However, 
these stains do not distinguish TC from AC, but the classification is based on 
the number of mitoses and presence of necrosis. 
PC tumors express several polypeptides such as GHRH, ACTH, serotonin, 
and calcitonin (Rosai & Ackerman 2011). These markers can be labeled 
immunohistochemically to study the association with clinical syndromes (La 
Rosa et al. 2019; Travis et al. 2015a).  
The differential diagnosis of PC tumor includes metastases from NETs of 
other origin, especially the gastrointestinal tract, metastatic medullary thyroid 
carcinoma (MTC), pulmonary paraganglioma, and small-cell carcinoma (den 
Bakker & Thunnissen 2013). Immunohistochemical labeling for thyroid 
transcription factor-1 (TTF-1), homeobox protein CDX-2, and pan-cytokeratin 
help in separating between these entities, except between a metastatic MTC 
and a PC tumor (Table 4). Here, differential diagnosis is based on elevated 
blood level of calcitonin in MTC (La Rosa et al. 2009).  
Evaluation of the Ki-67 antigen as proliferation index (PI) is a valuable tool 
in distinguishing a PC tumor from a small-cell carcinoma especially from small 
crushed biopsies where mitotic figures cannot be adequately assessed. Small-
cell carcinomas have a PI of >50% while PC tumors have a PI of <20% (Figure 
5F) (den Bakker & Thunnissen 2013). Data are conflicting regarding the Ki-67 
PI’s ability to separate between TC and AC, and the Ki-67 PI is not included in 
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Table 4. Immunohistochemical differential diagnosis of pulmonary carcinoid tumors. CK, 




TTF-1 CDX-2 pan-CK 
Pulmonary carcinoid + − + 
Metastasis from a 
gastrointestinal NET 
− + + 
Pulmonary 
paraganglioma 
− NA − 
Small-cell carcinoma + − + 
Metastatic medullary 
thyroid carcinoma 
+ − + 
 
 
2.4.9 TNM CLASSIFICATION AND STAGING 
 
There is no specific staging system for PC tumors but they are classified 
according to the Union for International Cancer Control/American Joint 
Committee on Cancer tumor, node, metastasis (TNM) staging system 
formulated for lung cancer in general (Brierley et al. 2017). Staging consists of 
radiological or surgical evaluation where the extent of the primary tumor is 
assessed together with the absence or presence of metastasis in regional lymph 
nodes and elsewhere in the body (Table 5). The clinical classification is 
essential for selecting the primary therapy whereas the pathological 
classification is used to guide adjuvant therapy and for prognosis estimation. 
After assigning the T, N, and M categories, they may be grouped to form stages 
















Table 5. Tumor, node, metastasis classification for lung tumors. Modified from Brierley et al. 
(2017). 
Primary tumor (T) 
TX 
Primary tumor cannot be assessed, or tumor was proved by the presence of 
malignant cells in sputum or bronchial washings but not visualized by imaging or 
bronchoscopy 
T0  No evidence of primary tumor 
Tis Carcinoma in situ 
T1 
Tumor ≤3 cm in greatest dimension, surrounded by lung or visceral pleura, 
without bronchoscopic evidence of invasion more proximal than the lobar 
bronchus (i.e. not in the main bronchus) 
 T1mi Minimally invasive adenocarcinoma 
 T1a Tumor ≤1 cm in greatest dimension 
 T1b Tumor >1 cm but ≤2 cm in greatest dimension 
 T1c Tumor >2 cm but ≤3 cm in greatest dimension 
T2 
Tumor >3 cm but ≤5 cm or tumor with any of the following features;  
- Involves main bronchus regardless of distance to the carina, but without 
involvement of the carina 
- Invades visceral pleura 
- Associated with atelectasis or obstructive pneumonitis that extends to the hilar 
region either involving part of or the entire lung 
 T2a Tumor >3 cm but ≤4 cm in greatest dimension 
 T2b Tumor >4 cm but ≤5 cm in greatest dimension 
T3  
Tumor more than 5cm but not more than 7cm in greatest dimension or one that 
directly invades any of the following: parietal pleura, chest wall (including 
superior sulcus tumors) phrenic nerve, parietal pericardium; or separate tumor 
nodule(s) in the same lobe as the primary 
T4 
Tumor more than 7cm or of any size that invades any of the following: 
diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal 
nerve, oesophagus, vertebral body, carina; separate tumor nodule(s) in a 
different ipsilateral lobe to that of the primary 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 
Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension 
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 
Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or 
contralateral scalene, or supraclavicular lymph node(s) 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
 M1a 
Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or 
pericardial nodules or malignant pleural or pericardial effusion 
 M1b Single extrathoracic metastasis in a single organ 
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Table 6. Pulmonary carcinoid tumor staging based on tumor, node, 
metastasis classification. Modified from Brierley et al. (2017). 
Stage T N M 
 
 
Occult carcinoma TX N0 M0  
Stage 0 Tis N0 M0  
Stage IA T1 N0 M0  
Stage IA1 T1mi N0 M0  
 T1a N0 M0  
Stage IA2 T1b N0 M0  
Stage IA3 T1c N0 M0  
Stage IB T2a N0 M0  
Stage IIA T2b N0 M0  
Stage IIB T1a, c, T2a, b N1 M0  
 T3 N0 M0  
Stage IIIA T1a, c, T2a, b N2 M0  
 T3 N1, M0  
 T4 N0, N1 M0  
Stage IIIB T1a, c, T2a, b N3 M0  
 T3, T4 N2 M0  
Stage IIIC T3, T4 N3 M0  
Stage IV Any T Any N M1  
Stage IVA Any T Any N M1a, M1b 
Stage IVB Any T Any N M1c  
 
 
2.4.10 MANAGEMENT OF LOCALIZED DISEASE 
 
The clinical practice guidelines for PC tumors are listed in Table 7. The goal of 
treatment is to control tumor growth and the secretory pattern of tumor cells.  
 





ENETS European Neuroendocrine Tumor Society Caplin et al. 2015 
NANETS North American Neuroendocrine Tumor Society Phan et al. 2010 
ESMO European Society for Medical Oncology Öberg et al. 2012 







The main and only curative treatment for PC tumor is surgical resection of the 
tumor preserving as much normal lung tissue as possible. Based on the 
literature, 85–97% of patients are operated on (Fink et al. 2001; Grøndahl et 
al. 2019; Herde et al. 2018). The surgical approach depends on the size, 
location, and subtype (TC or AC) of the tumor (Caplin et al. 2015). The 
preferred types of surgery are lobectomy, segmentectomy, and sleeve resection 
(Caplin et al. 2015; Phan et al. 2010; Öberg et al. 2012). Open surgery and 
thoracoscopic techniques are preferred, but bronchoscopy can be utilized for 
tumors without an extraluminal component. Intraoperative frozen sections of 
the resection margins are recommended in lung parenchyma sparing surgical 
techniques (Boyar Cetinkaya et al. 2017). Nodal dissection should be 
performed since up to 25% of TC tumors and >50% of AC tumors may present 
lymph node involvement that has prognostic value (Caplin et al. 2015; Phan et 
al. 2010; Öberg et al. 2012).  
Currently, there is no consensus on adjuvant therapy for resected PC 
tumor patients. NCCN guidelines recommend considering adjuvant 
cisplatin/etoposide, carboplatin/etoposide, or temozolomide therapy with or 
without radiation for certain ACs (resectable stage IIIA) (Shah et al. 2019). 
ENETS guidelines suggest adjuvant therapy for AC patients with positive 
lymph nodes and high proliferation index (PI) (Caplin et al. 2015). NANETS 
recommends against use of adjuvant treatment due to lack of clinical evidence 
(Phan et al. 2010). None of the guidelines recommend neoadjuvant treatment. 
 
2.4.11 SURVEILLANCE OF SURGICALLY TREATED PATIENTS 
 
Even if PC tumors commonly have an indolent behavior, they are able to 
metastasize. Recurrent disease is more often seen in AC patients (18–40%) 
than in TC patients (1–8%) (Aydin et al. 2011; Canizares et al. 2014; Cusumano 
et al. 2017; Grøndahl et al. 2019; Lou et al. 2013; Rea et al. 2007). The most 
frequent recurrence sites are the liver, lung, bones, mediastinal lymph nodes, 
and adrenal glands. Thus, after primary surgery, PC tumor patients should be 
followed up to detect possible recurrences. The liver, mediastinum, and 
abdominal lymph nodes as well as the lung, skin, and bones should be 
evaluated by radiology to exclude metastases (Caplin et al. 2015). In case of 
specific symptoms, brain metastases should be suspected (Caplin et al. 2015). 
For TC patients, conventional imaging together with chromogranin A 
measurement should be carried out at 3 and 6 months after the surgery and 
then every 12 months for the first 2 years. After that, annual chest X-ray 
coupled with plasma chromogranin A measurement and CT scan every 3 years 
are recommended. SRS or 68Ga-DOTA-peptide PET CT should be carried out 
at 12 months and then only on suspicion of recurrence (Caplin et al. 2015). 
 
 
Review of the literature 
34 
 
For AC patients, closer monitoring is recommended with CT imaging 3 months 
post-operative and then twice a year for 5 years, coupled with plasma 
chromogranin A measurement. After 5 years, a CT scan should be performed 
annually. As for TC patients, SRS or 68Ga-DOTA-peptide PET CT should be 
carried out at 12 months and thereafter only when clinically indicated (Caplin 
et al. 2015). 
Although not included in the current clinical practice guidelines, it was 
recently shown that the NETest can differentiate PC tumor patients with 
residual disease from those surgically cured (Filosso et al. 2018; Malczewska 
et al. 2019a). Thus, measuring circulating mRNA from peripheral blood may 
offer a follow-up option in the future.  
 
2.4.12 TREATMENT OF DISSEMINATED DISEASE 
 
The management of advanced, metastatic, or unresectable disease should be 
discussed in a multidisciplinary tumor board, preferably accompanied by a 
molecular geneticist (Figure 6). The goals are slowing down tumor growth and 
controlling symptoms from tumor burden or hormonal production. Quality of 
life is the core issue since there is no curative therapeutic option for metastatic 




Figure 6. Multidisciplinary team for the management of advanced disease (from 
Oronsky et al. 2017, p. 996, Fig 2, published under the CC BY-NC-ND license). 







Up to 30% of advanced PC patients present symptoms related to hormone 
secretion (Caplin et al. 2015). Carcinoid syndrome is the most frequent and 
can be treated with SSAs (Caplin et al. 2015; Phan et al. 2010; Shah et al. 2019; 
Öberg et al. 2012). Surgical resection of symptomatic liver metastases is 
reasonable especially when >90% of the tumor can be removed (Caplin et al. 
2015; Öberg et al. 2012). 
In asymptomatic PC patients with low tumor burden and a low tumor Ki-
67 PI, watchful waiting on the basis of regular (interval of 3–6 months) cross-
sectional imaging can be considered (Caplin et al. 2015; Shah et al. 2019). 
SSTR-positive patients can be treated with SSAs to control tumor growth 
(Caplin et al. 2015; Shah et al. 2019). To date, no prospective trials on the first-
generation SSAs – octreotide and lanreotide – in the treatment of PC patients 
have been conducted. The knowledge acquired from studies involving 
gastroenteropancreatic NET patients, especially from PROMID and 
CLARINET trials, created the rationale to use these SSAs also for PC patients 
(Caplin et al. 2014, 2016; Rinke et al. 2009, 2017). In addition, the efficacy and 
safety of SSAs in patients with metastatic PC tumor has been reviewed 
retrospectively (Bongiovanni et al. 2017; Sullivan et al. 2017). Both studies 
concluded that SSAs show antitumor activity in terms of disease control rate 
and progression-free survival (PFS). Currently, three prospective multicenter 
studies are ongoing to confirm the efficacy and safety of lanreotide in the 
treatment of PC tumor patients either alone (SPINET trial, NCT02683941) or 
in combination with temozolomide (ATLANT trial, NCT02698410) or 
metformin (MetNET-2 Trial, NCT02823691) (ClinicalTrials.gov 2019).  
A multi-SSTR-targeting SSA called pasireotide was evaluated in the LUNA 
trial that compared pasireotide versus everolimus versus the combination of 
pasireotide with everolimus in advanced lung and thymic carcinoids (Ferolla 
et al. 2017). Pasireotide showed preliminary evidence of activity but the 
primary endpoint, the proportion of patients without progression at month 9, 
did not differ between the three arms. 
 
 
Peptide receptor radionuclide therapy 
 
Peptide receptor radionuclide therapy (PRRT) is a systemic radiotherapy 
based on intravenous administration of radiolabeled SSAs. PRRT with 
177Lutetium-DOTA-peptide or 90Yttrium-DOTA-peptide can be considered if 
progression occurs under SSAs (Caplin et al. 2015; Shah et al. 2019). Multiple 
studies have shown the utility of PRRT in NET patients, including a minor 
percentage of PC tumor patients. Imnof et al. (2011) conducted one of the 
largest prospective studies evaluating Yttrium-labeled SSAs in 1109 NET 
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patients including 84 PC patients. In PC patients, radiological response was 
observed in 28.6% and clinical response in 38.1%. No complete response was 
achieved. Brabander et al. (2017) studied retrospectively long-term efficacy, 
survival, and safety of Lutetium-labeled SSAs in 610 NET patients of which 23 
were PC patients. In PC patients, PRRT obtained a 30% overall response rate 
without any complete response. Stable disease was seen in 6 (30%) patients. 
 
 
Chemotherapy and radiotherapy 
 
PC tumors progress in general slowly and are thus less responsive to systemic 
chemotherapy. However, according to the guidelines, systemic chemotherapy 
with or without radiation therapy can be given to patients with progressive 
unresectable PC tumor for palliative treatment (Caplin et al. 2015; Shah et al. 
2019). The same applies to external local irradiation of bone and brain 
metastasis (Öberg et al. 2012). 
Only a few studies have evaluated the role of systemic chemotherapy in PC 
patients including the following drugs: 5-fluorouracil, capecitabine, 
doxorubicin, dacarbazine, streptozocin, cyclophosphamide, platinum 
derivatives, etoposide, and temozolomide. All these drugs showed overall 





According to the ENETS guidelines, the mammalian target of rapamycin 
inhibitor, everolimus, may be a therapeutic option after failure of other 
treatments (Caplin et al. 2015). However, since launching the guidelines, 
several studies have shown the benefit of everolimus. Everolimus was first 
investigated in PC patients (n=44) with advanced and functional tumor in the 
RADIANT-2 study that assessed the combination of everolimus with 
octreotide long-acting release (LAR) versus placebo with octreotide LAR. 
Everolimus with octreotide LAR provided an improvement of 8 months in PFS 
(from 5.6 to 13.6 months) (Fazio et al. 2013). Later, the RADIANT-4 study 
enrolled 90 PC patients with advanced, progressive, and non-functional tumor, 
randomly assigned to receive everolimus or placebo. The PC patients who 
received everolimus had a clinical improvement of 5.6 months (9.2 vs 3.6 
months) in PFS compared with placebo (Fazio et al. 2018). Thus, everolimus 
might be considered a valid treatment option for patients with advanced 
progressive PC tumors. 
Targeted therapies that inhibit angiogenesis may also play a role in the 
treatment of advanced PC patients. To date, only relevant data were presented 





NET and carcinoid tumor patients including 14 stomach and pulmonary 
carcinoid tumors. According to the study, carcinoid tumor patients had an 
overall response rate of 2.4%, while a stable disease for over 6 months was 
achieved in 56% of the patients. Currently, several clinical trials investigating 
antiangiogenic agents are recruiting NET patients, including PC patients 
(ClinicalTrials.gov 2019). 
Immune checkpoint inhibitors targeting programmed cell death protein 1 
(PD-1) or programmed death ligand 1 (PD-L1) are part of standard care in the 
treatment of advanced NSCLC (Planchard et al. 2019). In PC patients and 
other NET patients, their efficacy and safety are under evaluation. First results 
are from KEYNOTE-028 and KEYNOTE-158 clinical trials, which studied the 
efficacy and safety of PD-1 targeting pembrolizumab in NET patients, 
including PC tumor patients. The studies showed that pembrolizumab is 
generally well tolerated and that 4–10% of the patients had an objective 
response, while stable disease was achieved in 57–71% of the patients 
(Mehnert et al. 2017; Strosberg et al. 2019). Several other clinical trials are 




In contrast to high-grade small-cell carcinoma and LCNEC, PC tumor patients 
have a relatively favorable prognosis. TC patients with resectable disease show 
a 5-year survival exceeding 90%, and a 10-year survival between 82–93% 
(Cusumano et al. 2017; Filosso et al. 2002; Fink et al. 2001; Rea et al. 2007). 
Among AC patients the 5-year survival ranges from 47 to 78% and the 10-year 
survival is between 35 and 72% (Beasley et al. 2000; Cusumano et al. 2017; 
Daddi et al. 2014; Filosso et al. 2002; Fink et al. 2001). Of note, recurrence can 
occur a decade after the resection of the primary tumor (Gustafsson et al. 
2008a).  
Various clinical and histopathological parameters are known to be 
associated with the survival of PC tumor patients. The histopathological AC 
subtype and presence of distant metastasis are almost unanimously 
recognized to be associated with worse outcome (Cusumano et al. 2017; Daddi 
et al. 2014; Hobbins et al. 2016). According to most studies, lymph node 
involvement is associated with a shorter survival but opposite reports exist, 
too (Cusumano et al. 2017; Kneuertz et al. 2018; Okereke et al. 2016). Other 
reported prognostic factors include TNM stage and primary tumor size 
(Beasley et al. 2000; Daskalakis et al. 2018). 
High tumor PI, as measured by Ki-67 expression from the surgical 
specimen, is also associated with shorter survival in many studies. Clay et al. 
(2017) reported that the Ki-67 PI is an independent prognostic factor for 
relapse-free survival. They categorized PC tumor patients according to the Ki-
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67 PI into three subgroups (Ki-67 PI <5%, 5 to <10%, or 10–15%) and showed 
that the higher the Ki-67 PI, the shorter the relapse-free survival. Marchevsky 
et al. (2018) performed a similar study where they categorized TC patients into 
two subgroups (Ki-67 PI <5% or ≥5%) with different overall survival (OS): 
median OS for the TC patients with Ki-67 PI ≥5% was less than 5 years, while 
95% of the TC patients with Ki-67 PI <5% were alive at year 5. However, both 
studies involved a limited number of patients (94 and 82, respectively). 
SSTR expression has also been studied as a prognostic factor in PC tumors. 
Kaemmerer et al. (2015) reported SSTR1 expression to be a strong prognostic 
marker in pulmonary neuroendocrine neoplasms. On the other hand, 
Daskalakis et al. (2018) stated that SSTR1–5 expression is not associated with 
survival. 
Effective and accurate circulating biomarkers for PC tumors are currently 
unavailable (Modlin et al. 2017). Plasma chromogranin A is recommended for 
the follow-up of PC tumor patient but its prognostic value is limited 
(Malczewska et al. 2019b). NETest was recently shown to accurately 
distinguish progressive disease from stable disease but more data are needed 
to determine its clinical utility in PC tumors (Malczewska et al. 2019a). 
Despite the indolent nature of PC tumors, post-resection recurrence occurs. 
Thus, the development of biomarkers that could be used for disease 









Biospecimens, such as tissue and blood samples, are crucial for medical 
research. Biobanks collecting, processing, storing, and distributing 
biospecimens coupled with extensive patient data are resources enabling basic, 
translational, and clinical research as well as development of personalized 
therapies. Currently, five main models of biobanks are conceptualized: the 
prospective model, the classic biobanking model, the population-based model, 
the data focused model, and the clinical archival tissue model (Table 8) 
(Grizzle et al. 2019). Usually, each biobank follows a primary model but also 
incorporates components from other models. 
On a European level, over 600 biobanks in 17 countries have been 
established to provide researchers with biospecimens and associated clinical 
data (Holub et al. 2016). These countries are involved in the Biobanking and 
Biomolecular Resources Research Infrastructure – European Research 
Infrastructure Consortium (BBMRI-ERIC). The mission of BBMRI-ERIC is to 
bring together the European biobanks by offering quality management 
services and support for ethical, legal, and societal issues as well as online tools 
and software solutions. 
The legislation regarding and definition of a biobank, as well as 
organization of biobanks across European countries vary considerably. The 
best-known biobanks with different biospecimen collection strategies in 
Europe include the British UK Biobank, Austrian Biobank Graz, and Swedish 
U-CAN. UK Biobank is a population-based biobank that recruited 500 000 
volunteers aged 40–69 years between 2006 and 2010. The volunteers 
provided blood, urine, and saliva samples as well as detailed information 
about themselves. Moreover, they agreed to have their health followed. In 
addition to biospecimens and phenotype and health data, UK Biobank also 
offers genome-wide genotyping data for all 500 000 participants and is 
planning to provide exome and whole genome sequencing data of 50 000 
participants by the end of 2020. To date, researchers have submitted more 
than 1400 sample and data access applications and published over 800 papers 
that utilized the biobank’s samples and data (UK Biobank 2019). 
In contrast to UK Biobank, Biobank Graz collects biospecimens and clinical 
data mainly from patients in a population-based manner. Biobank Graz is a 
research facility of the Medical University of Graz, Austria, and is closely 
related to University Hospital Graz. It hosts more than 20 million 
biospecimens including blood, serum, plasma, buffy coat, fresh frozen tissues, 
and formalin-fixed paraffin-embedded (FFPE) tissues from more than 2.5 
million patients. All samples can be linked to clinical data of the patients. In 
addition to biospecimen distribution, Biobank Graz also offers analysis 
services. Unfortunately, data on the number of biospecimens distributed to 
research projects or published papers is not available (Biobank Graz 2019). 
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The third example of European biobanks is Swedish U-CAN. It differs from 
both UK Biobank and Biobank Graz in the sense that it collects biospecimens 
and data on selected cancer patients before, during, and after therapy. The 
main biospecimen types are blood, fresh frozen tissue, DNA, and RNA. Clinical 
information together with imaging data are widely collected. Since U-CAN’s 
launch in 2011, more than 70 research projects have been approved to use the 
biospecimens and data (U-CAN 2019). 
 
2.5.1 FINNISH BIOBANK ACT 
 
Previously, Finnish legislation on medical research was built on the principle 
that study-specific informed consent must be obtained from a participant in 
order to use their biospecimen and data. This led to underuse of existing 
sample and data collections. Also, the study participants had no right to know 
the results of the studies they were involved in. To improve the situation, the 
Finnish Biobank Act entered into force in September 2013 providing the legal 
framework for biobanking activities (Biobank Act 2012). The Act regulates on 
conditions for establishing and operating a biobank, on sample donor’s rights 
and the integrity of their samples and data as well as on granting access to 
biospecimens and related information. The Act applies to all biobanks, 
whether public or private, clinical or research based. 
According to the Act, a biobank can be established by a private person or 
by a public institution having the required qualifications. The National 
Committee on Medical Research Ethics reviews each biobank application and 
after a positive statement, the applicant issues the notification for establishing 
a biobank to the National Supervisory Authority for Welfare and Health 
(Valvira).  
Informed consent given in writing is the primary justification for collecting, 
processing, storing, and distributing biospecimens and related clinical data. 
Prior to giving the consent, the potential participant must be provided with 
sufficient information on the nature of biobank research as well as a 
participant’s rights. The consent is broad and covers unspecified future 
research purposes where biospecimens and data can be utilized. In addition to 
informed consent, the Act affords a pathway for transferring diagnostic 
samples to a biobank. This pathway concerns samples that were stored within 
the healthcare system at the time the Act entered into force. It should be noted 
that the transfer must not jeopardize the possible future need for the samples 
in patient care, a regional ethics committee must approve the transfer, and the 
persons concerned must be notified and given the possibility to opt-out. The 
same pathway also applies to biospecimens and data that were previously 
collected for research purposes. 
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One of the guiding principles of the Act is equal access to biospecimens and 
data. According to the Act, Finnish biobanks are regarded as common 
resources and are available to all researchers whether academic or industrial, 
in Finland or from abroad. This means that biobanks evaluate all sample and 
data applications based on the same criteria that cover the scientific and 
technological excellence as well as ethical aspects of the proposed project. 
Biobanks can deny access to their material only under certain conditions, for 
example to preserve a rare collection, or if the proposed project does not fulfill 
the sample access criteria. On the other hand, researchers are obligated to 
return the results of their analysis to enrich the information in the biobanks. 
The process for applying for samples and data is presented in Figure 7.  
 
 
Figure 7. Process for applying samples and data from a Finnish biobank. 
 
2.5.2 FINNISH BIOBANK INFRASTRUCTURE 
 
Finland is recognized as a highly successful environment for medical research 
for three main reasons. First, the Finns have a relatively isolated gene pool, 
which is an advantage in genetic studies (Peltonen et al. 1999). Secondly, the 
Finns for the most part trust researchers, and they are interested in science 
and are willing to contribute (Snell & Tupasela 2012). Thirdly, unique personal 
identification numbers together with national and regional health registers 
and a large amount of biospecimens provide researchers with a versatile 
resource for population- or disease-based studies. Fourthly, national 
guidelines for treatment are available for more than 100 diseases and they are 
applied despite the geographic location of the health-care unit (The Finnish 
Medical Society Duodecim 2019). 
Collecting biospecimens and data for medical research is nothing new in 
Finland. The Social Insurance Institution launched the first population survey, 
called the Finnish Mobile Clinic, in 1966 with the aim of searching for tools for 
the prevention and early detection of chronic diseases like coronary heart 
disease and diabetes mellitus (Knekt et al. 2017). Moreover, the Finnish Twin 
Cohort study at the University of Helsinki began in 1974. Hundreds of peer-
reviewed scientific papers have been published from this valuable and 
















researchers and research groups in universities and hospitals have collected 
patient samples and clinical data for decades. 
After the specific legislation for biobanking in 2013, 10 biobanks were 
established (Table 9 and Figure 8). Six of them are regional, hospital-
integrated biobanks collecting biospecimens and clinical data from their 
patients. The rest are nationwide biobanks that administer biospecimens and 
data from population-based cohorts, blood donors, or patients with 
hematological malignancies. One of the biobanks is owned by a private health-
care provider with the aim of collecting samples from its customers (Valvira 
2019). 
 
Table 9. Finnish Biobanks as of October 2019. Modified from Valvira (2019). 









University Hospital District 
Public 2015 
Finnish Clinical Biobank 
Tampere 
Regional, Tampere 
University Hospital District 
Public 2015 
Central Finland Biobank 
Regional, Jyväskylä 
Central Hospital District 
Public 2015 
Biobank of Eastern 
Finland 
Regional, Kuopio 
University Hospital District 
Public 2015 
Biobank Borealis 
Regional, Oulu University 
Hospital District 
Public 2015 
THL Biobank Nationwide Public 2014 
FHRB Biobank Nationwide Public 2014 
Blood Service Biobank Nationwide Private 2017 
Terveystalo Biobank 
Finland 
Nationwide Private 2017 
 
 
All hospital-integrated biobanks collect biospecimens in a population-based 
manner with the main sample type being EDTA blood. In addition, fresh 
frozen tissue samples from cancer patients are collected in most of the 
hospital-integrated biobanks, and more comprehensive biospecimen 
collection can be tailored in selected disease areas based on research needs. 
The THL Biobank belongs to the National Institute for Health and Welfare 
(THL). It administers a remarkable amount of population-based and disease-
specific biospecimen and data collections, such as the Finnish Mobile Clinic 
Survey, Finnish Twin Cohort study, and FINRISK studies (THL Biobank 2019). 
The Blood Service Biobank collects biospecimens from blood donors and is 
specialized in distributing material for transfusion medicine research (Blood 
Service's Biobank 2019). The Finnish Hematology Registry and Clinical 
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Biobank (FHRB) provides researchers with blood, skin, and bone marrow 
samples collected from hematological patients at different disease phases, 
coupled with extensive clinical follow-up data (FHRB 2019). 
 
Within clinical pathology, tissue samples and related data have been archived 
for decades as a backup for routine diagnostic procedures. Today, most of 
these collections have been transferred into hospital-integrated biobanks and 
allow scientists to create significant retrospective cohorts even with rare 
diseases. It is estimated that Finnish hospital-integrated biobanks host FFPE 
samples from nearly 3 million Finns (BBMRI.fi 2019). 
Finnish biobanks are networking in two different arenas. BBMRI.fi, the 
Finnish National Node of BBMRI-ERIC, aims to standardize and harmonize 
biobanking procedures (BBMRI.fi 2019). The goal of the other arena, the 
Finnish Biobank Cooperative (FINBB), is to provide biobanks with sample and 
data processing services as well as to offer support in legal and communicative 
issues. Moreover, FINBB acts as a one stop shop for researchers willing to 
access biospecimens and data from multiple Finnish biobanks. Currently, only 
hospital-integrated biobanks and THL Biobank are involved in FINBB (FINBB 
2019). 






Finnish biobanks have a strong aim to support medical research by providing 
their valuable materials to high-quality studies. Several hundred research 
projects utilizing biobank samples and data are ongoing (BBMRI.fi 2019). One 
of the most ambitious projects is the FinnGen study that involves 500 000 
unique DNA samples from the biobanks (FinnGen 2019). FinnGen combines 
genome information derived from these samples with national health registry 
data to produce medical innovations. From the biobanks’ point of view, 
FinnGen is a valuable project since the generated genome information will be 
returned to the biobanks to enrich their biospecimen and data collections. 
 
2.5.3 BIOBANKING FROM THE PERSPECTIVE OF PARTICIPANTS 
 
In a pan-European study involving 32 countries, Nordic populations were 
among the most willing to participate in biobanking, and the Finns were the 
most compliant to give broad consent (Gaskell et al. 2013). However, another 
study shows that 60% of Finns have never heard of biobanks, and 72% of those 
who have heard estimate that they know nothing about biobanks (9%) or that 
their knowledge is limited (63%) (Snell 2017). Despite this, 44–84% would 
give a biobank consent and donate a blood sample (Snell 2017; Snell & 
Tupasela 2012). High participation intention reflects the fact that Finns trust 
science, universities, and public healthcare but this does not mean that their 
support is unqualified or lacks criticism. The most common concerns were the 
lack of privacy in data protection and the misuse of biospecimens in the form 
of selling them abroad (Snell & Tupasela 2012).  
Finnish blood donors’ attitudes towards biospecimen and data donation for 
biobanking have also been assessed (Raivola et al. 2019). The vast majority of 
the study participants held a positive attitude towards joining the Blood 
Service Biobank. The study identified three issues the biobanks should focus 
on to build up participant trust: their institutional reputation, participant 
experience, and dialogue with the participants. 
By the end of 2018, nearly 250 000 Finns had given their prospective 
consent to biobanking (BBMRI.fi 2019). According to the Finnish Biobank Act, 
participants can track the use of their samples and data. Everyone has the right 
to know whether his or her sample and data are stored in a biobank and to 
which studies the material has been provided. Most of the biobanks provide 
on their webpage a form, which the participant can fill in to get detailed 
information on his or her biobank samples and data. In addition, the 
participants have the right to obtain information and to get to know the 
meaning of the analysis results derived from his or her sample. Participants 
can also restrict or prohibit the use of their samples and data at any stage 
without specifying the reason (Biobank Act 2012).  
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2.5.4 BIOBANKING FROM A RESEARCHER’S PERSPECTIVE 
 
From a researcher’s point of view, the main value of biobanking is the 
possibility to obtain access to readily available biospecimens and data. 
Transferring research or clinical sample collections to a biobank enables novel 
usage of them without first obtaining new consent from each participant. Also, 
consented participants can be re-contacted by the biobank to donate different 
sample types or to collect more data. Thus, biobanks can also serve as research 
cohort providers. The process for accessing biobank material is detailed in 




Figure 9. Schematic presentation of how to access biobank samples and data. 
 
 
Researchers also have certain obligations to the biobanks. The results of their 
studies, including the so-called raw data, are to be returned to the biobank. 
This way data will accumulate in the biobanks and may benefit other 





3 AIMS OF THE STUDY 
The major aim of this thesis was to find tissue-based biomarkers in PC tumors 





1. To determine serotonin, ACTH, calcitonin, TTF-1, and Ki-67 expression as 
well as their prognostic value in PC tumors.  
 
2. To study different clinicopathological variables as prognostic factors in PC 
tumor patients. 
 
3. To study the SSTR expression profile and its diagnostic, predictive, and 
prognostic relevance in PC tumors. 
 
4. To evaluate the expression and the prognostic value of PD-1 and PD-L1 in 
PC tumors. 
 
5. To assess the performance of Finnish hospital-integrated biobanks in a 








4 MATERIAL AND METHODS 
4.1 PATIENT COHORTS AND TISSUE SAMPLES 
All studies (I–IV) included consecutive patients with a PC tumor diagnosis, 
operated on between January 1990 and August 2013 at the Helsinki University 
Hospital, Helsinki, Finland. Tumor samples of these patients were obtained 
from the Helsinki Biobank. In addition, studies II and III included tumor 
samples of the PC patients operated on between January 1990 and August 
2013 at the Turku University Hospital, Turku, Finland, obtained from the 
Auria Biobank, as well as tumor samples of the patients operated on between 
January 2000 and August 2013 at the Kuopio University Hospital, Kuopio, 
Finland, obtained from the Biobank of Eastern Finland. In study IV, tumor 
samples of all PC patients operated on between January 1990 and August 2013 
and found in the Finnish hospital-integrated biobanks were involved (Figure 
10). A starting point of January 1, 1990 was chosen for two reasons: 1) to obtain 
a long follow-up time for the patients and 2) since the routine tissue sample 
processing protocols were standardized around 1990. The last date was chosen 
be to August 31, 2013 since samples processed in clinical pathology 
laboratories before that date were transferred to biobanks. In addition, this 
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Finnish Clinical Biobank Tampere






The number of patients varies slightly (6%) between studies II and III (Table 
10) since some of the tumor samples were detached from the TMA slides 
during immunohistochemical processing and were excluded from the analysis. 
The same applies to the samples received from the Helsinki Biobank for 
studies I and IV.  
 
Table 10. Pulmonary carcinoid tumor material in the original publications. 
AC, atypical carcinoid; TC, typical carcinoid. 
Study I II III IV 
 
 
Number of patients 133 178 168 224 
Number of TCs 100 138 131 182 
Number of ACs 33 40 37 42 
 
 
Tissue samples from the primary tumors were collected from the archives of 
the biobanks. Histologic specimens were re-evaluated from original 
microscopy slides by a pathologist with special expertise in pulmonary 
pathology (Kaisa Salmenkivi, Paula Vainio, Elisa Lappi-Blanco, and Teijo 
Kuopio). Tumors were classified as TC or AC based on the 2015 WHO 
classification criteria (Travis et al. 2015a). Neuroendocrine origin and 
epithelial differentiation were further confirmed with immunohistochemical 
labeling against chromogranin A, synaptophysin, and pan-keratin. Associated 
clinical data were collected in the biobanks from the hospital records. Survival 
data were retrieved from the Finnish Population Register Centre and the cause 
of death data from Statistics Finland.  
 
4.2 PULMONARY CARCINOID INCIDENCE DATA 
PC tumor and lung cancer incidence data for study IV were retrieved from the 
Finnish Cancer Registry (FCR). FCR operates under THL with the aim of 
collecting nationwide data on cancer incidence in Finland. Information on 
cancer cases is received from both public and private hospitals, laboratory 
reports, and death certificates. Registration started in 1953 and became 
compulsory for health-care professionals in 1961. The degree of data 
completeness for lung cancers is estimated to be 97.2%. We applied for 
information  on  lung  cancer  and  PC tumor incidence between 1990 and 2013. 
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The age-standardized incidence rates per 100 000 person-years were 
calculated using the world standard population (1966) for weights. 
4.3 DIGITAL PATHOLOGY AND WHOLE-SLIDE IMAGING 
The concept of digital pathology refers to the use of information technology in 
pathology with an aim to, for example, analyze and share images. In this study, 
whole-slide imaging (WSI) had an essential role. The basic component of a 
WSI system is a slide scanner able to create a digital reproduction of the entire 
histology slide. The WSI scanner consists of a light source, slide stage, 
objective lenses, and a high-resolution camera for image capture. The scanner 
captures images tile by tile or in lines. Multiple images are captured and 
digitally stitched to generate a digital slide of the original glass slide (Zarella et 
al. 2019). 
In this study, one or two representative original diagnostic histology slides 
from each tumor were digitized. Tumor re-evaluation as well as annotations 
for the construction of TMA blocks were performed on digitized slides. In 
addition, all immunohistochemically stained slides were digitized, and the 
staining results were interpreted either manually or with the help of image 
analysis software. 
4.4 NEXT-GENERATION TISSUE MICROARRAY 
The TMA technique was first introduced in 1998 by Kononen et al. and it 
revolutionized the investigation of potential tissue biomarkers (Kononen et al. 
1998). This array construction involves making a hole in the recipient TMA 
block, acquiring a cylindrical core sample (0.6–2.0 mm in diameter) from the 
donor block and depositing that core into the recipient TMA block. Repeated 
transfer of tiny tissue cores leads to the construction of a TMA block that 
contains hundreds of samples. This array construction method was originally 
manual and thus laborious, demanding a meticulous approach. In addition, 
the annotations were less exact when only marked with a marker pen on 
hematoxylin and eosin (H&E) stained slides.  
Next-generation TMA was introduced in 2014 (Zlobec et al. 2014). This 
approach, as for the previous one, involves careful planning and design of the 
TMA. In addition, next-generation TMA involves digital pathology and 
automated tissue microarraying to enhance the precision, flexibility, and 
speed of the TMA technique. 
For construction of the TMA blocks for this study, the most suitable FFPE 
tissue block per tumor was selected based on the original microscopy slides. A 
fresh H&E stained slide from that block was prepared and digitized. 





with the following principles: two cores from the middle of the tumor, two 
cores from the tumor border, two cores from a non-tumor area, and one core 
from the bronchus, if applicable. The TMAs were constructed in the biobanks 
with automated tissue microarrayers (TMA Grand Master, 3DHISTECH, 
Budapest, Hungary or Galileo TMA CK4500 microarrayer, Isenet, Milan, Italy) 
using 1 mm punches. 
4.5 IMMUNOHISTOCHEMISTRY  
The TMA sections obtained from the biobanks were immunolabeled against 
chromogranin A (chrom A), synaptophysin (SYP), pan-keratin (pan-CK), Ki-
67, TTF-1, ACTH, calcitonin, serotonin, SSTR1–5, PD-1, PD-L1, and CD8. 
Chrom A and SYP were used to confirm the neuroendocrine origin and pan-
CK to verify the epithelial differentiation. Ki-67 antibody was used to confirm 
that the tumor was PC tumor, not small-cell carcinoma. Another important 
aspect was to study Ki-67 PI as a diagnostic and prognostic marker. TTF-1 was 
labeled to study whether it could stratify tumors into TC and AC and whether 
it would have prognostic value. Immunohistochemical expression of ACTH, 
calcitonin, and serotonin was evaluated in order to study whether they are 
associated with survival. SSTR1-5 were labeled since NETs are known to 
express SSTRs but comprehensive reports on their expression and its clinical 
significance in PC tumors is lacking. Immunohistochemical labeling of PD-1, 
PD-L1, and CD8 was performed to increase understanding of their expression 
and association with clinical parameters in PC tumor patients. 
Staining of the TMA slides was performed in three different clinical or 
research laboratories. Chrom A, SYP, pan-CK, Ki-67, TTF-1, SSTR2, and CD8 
were stained at the Department of Pathology, HUSLAB, Helsinki University 
Hospital with a BenchMark XT or ULTRA instrument and an ultraView or 
OptiView Universal DAB Detection Kit (Ventana Medical Systems, Tucson, AZ, 
USA). Labeling against ACTH, calcitonin, and serotonin was similarly 
performed at HUSLAB with an AutoStainer 480 instrument (Lab Vision Corp., 
Fremont, CA) utilizing EnVision Detection Systems (Dako, Agilent Pathology 
Solutions, Santa Clara, CA, USA). 
SSTR1 and SSTR3–5 were stained in the research laboratory at the 
Department of Pathology, University of Helsinki with an AutoStainer 480 
instrument (Lab Vision Corp.) utilizing EnVision Detection Systems (Dako). 
PD-1 and PD-L1 were immunolabeled at the Department of Pathology, Central 
Finland Central Hospital, Jyväskylä, Finland using a Bond-III instrument and 
a Bond Polymer Refine Detection Kit (Leica Biosystems, Nussloch, Germany). 
This particular laboratory-developed PD-L1 assay was chosen since it was 
validated for clinical practice.  
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Different pretreatment conditions as well as detection kits and instruments 
were used for different antibodies (Table 11). Briefly, sections were 
deparaffinized and antigen retrieval was performed. The primary antibodies 
were incubated, and the immunoreactions were visualized using polymer-
based kits. All slides were counterstained with hematoxylin. Appropriate 
positive and negative controls were used. 
 
Table 11. Features of the antibodies and staining protocols used for immunohistochemistry. 
ACTH, adrenocorticotropic hormone; chrom A, chromogranin A; CK, cytokeratin; Inc., 
incubation; RTU, ready to use; SYP, synaptophysin; TTF-1, thyroid transcription factor-1. 




Chrom A Dako DAK-A3 1:800 32 CC1 std ultraView 
SYP Ventana SP11 RTU 32 
CC1 mild + 






RTU 12 CC1 std ultraView 
Ki-67 Dako MIB-1 1:100 32 CC1 std ultraView 
TTF-1 Novocastraa SPT24 1:100 80 CC1 std ultraView 
ACTH NeoMarkersb Polyclonal 1:200 30 None EnVision 
Calcitonin Dako Polyclonal 1:2500 30 None EnVision 
Serotonin Dako 5HT-H209 1:10 30 None EnVision 




SSTR2 Abcam UMB1 1:300 32 CC1 std OptiView 
SSTR3 Abcam UMB5 1:7000 60 Citrate pH 6.0 EnVision 
SSTR4 Bio-Radd sstr4 1:500 30 Citrate pH 6.0 EnVision 














CD8 Novocastra 4B11 1:50 60 CC1 ultraView 
 
a Novocastra, Leica Biosystems, Nussloch GmbH, Germany; b Lab Vision Corp., Fremont, 
CA, USA; c Abcam, Cambridge, UK; d Bio-Rad, Hercules, CA, USA; e Spring Bioscience, 
Pleasanton, CA, USA; f Cell Signaling Technology, Danvers, MA, USA  
 
4.6 SCORING AND IMAGE ANALYSIS SOFTWARE 
Scoring of immunohistochemical stainings was performed independently by 
two or three observers, of which one was a pathologist (Johanna Arola and 





Teijo Kuopio, Maarit Ahtiainen, and Tiina Vesterinen in study III, and 
Johanna Arola and Tiina Vesterinen in study IV). The scoring criteria are 
shown in Table 12. 
 








Positive/negative. Positive if >90% of the neoplastic cells showed 




Positive/negative. Positive if >90% of the neoplastic cells showed 
at least moderate membranous or cytoplasmic intensity. 




Percentage of the nuclei of the neoplastic cells showing at least 
moderate intensity. Counted with QuPath software (Bankhead et 
al. 2017) or ImmunoRatio software (Remes et al. 2012) from the 




Positive/negative. Positive if >10% of the nuclei of the neoplastic 




Positive/negative. Positive if at least one neoplastic cell showed 
strong cytoplasmic staining. 
Calcitonin  I Same as ACTH 




Cytoplasm: intensity 0–4 (negative, weak, moderate, strong) and 
% of the neoplastic cells showing cytoplasmic staining. 




0: no staining 
1: partial membranous positivity in <10% of the neoplastic cells 
2: partial membranous positivity in ≥10% of the neoplastic cells 
3: circumferential membranous positivity in the neoplastic cells 
4: strong, circumferential membranous positivity in >95% of the 
neoplastic cells 
(Modified from Elston et al. 2015 and Korner et al. 2012) 




Number of intratumoral lymphocytes showing at least dim 




Positive/negative. Positive if ≥1% of the neoplastic cells showed 




Number of intratumoral lymphocytes showing at least moderate 
membranous expression per mm2 
 
* For statistics, the SSTR1 and SSTR3–5 scores were grouped into two categories: positive 
(if cytoplasmic staining intensity was at least moderate in ≥5% of the neoplastic cells and/or 
when the membrane pattern was observed with score 2–4) and negative (all other staining 
patterns) 
** For statistics, the SSTR2 scores were grouped into two categories: positive (scores 2–4) 
and negative (scores 0–1) 
*** For statistics, expression was categorized into low and high expression based on the 
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In studies I and III, the Ki-67 PI and the CD8 expression, respectively, were 
analyzed with open-source QuPath software (Bankhead et al. 2017). First, the 
digital TMA slide images were imported, and automated dearraying was 
performed to separate single tissue cores. For Ki-67, cell detection channel 
“Hematoxylin + diaminobenzidine (DAB)” was launched to calculate the 
number of DAB and hematoxylin stained nuclei. The Ki-67 PI was further 
determined by dividing the number of DAB stained nuclei by the total number 
of nuclei. For CD8, a batch analysis was applied across all TMA cores to 
identify the tissue within each core and to calculate its area. Then the number 
of CD8 positive cells per mm2 was calculated based on color deconvolution. 
ImmunoRatio, a freely available, web-based image analysis application, 
was utilized in study IV for assessing the Ki-67 PI. ImmunoRatio does not 
support importing digital whole slides but the user captures an image of the 
area intended to be analyzed (Tuominen et al. 2010). ImmunoRatio then 
utilizes a color deconvolution algorithm to separate DAB and hematoxylin 
stains. After this, nucleus segmentation is performed, and the percentage of 
DAB stained nuclear area in the total nuclear area is calculated. 
4.7 STATISTICAL ANALYSIS 
In studies I–III, differences in the dichotomous or nominal variables between 
the groups were calculated with the Fisher’s exact test. The Kruskal–Wallis 
and Mann–Whitney U tests were used for continuous variables in studies II 
and III. Spearman’s rank correlation coefficient was used for the pairwise 
correlation analyses in study II.  
In all studies, the Kaplan–Meier method with the log-rank test was applied 
to estimate cumulative survival probabilities and to graphically display the OS 
and the disease-specific survival (DSS) probability curves. The exact 95% 
confidence intervals (CIs) were calculated for the survival rates. The 
significance of hazard ratios (HRs) for different variables was tested with the 
univariate Cox survival regression model in studies I, II, and IV. Receiver 
operating characteristics curves were used to estimate the cut-off values for 
continuous variables in studies I and IV. For the tumor size, a cut-off value of 
2.5 cm was chosen based on using the local maximum of Youden’s index in 
receiver operating characteristic analysis. In all studies, survival was 
calculated from the date of primary tumor resection to the last date of follow-
up or death, and non-disease-specific deaths were censored. In study II, 
duration of the clinical response and benefit from the first line SSA or PRRT 
were measured from the date of the start of the treatment to the date of the 
start of chemotherapy or the date of death. 
A significant difference was predetermined to be a P value <0.05 and a two-





expert (Harri Mustonen) using IBM SPSS Statistics for Windows, Version 24.0 
(IBM Corp., Armonk, NY, USA) and SAS for Windows 9.4 (SAS Institute, Cary, 
NC, USA). In addition, MedCalc Software, Version 18.5 (MedCalc Software, 
Ostend, Belgium) was used to graphically display the survival curves in study 
II. 
4.8 APPROVALS 
The Finnish Biobank Act provides a lawful basis for using biobank samples 
and data for research without a project-specific consent from the patients. 
However, each biobank (Helsinki Biobank, Auria Biobank, Biobank of Eastern 
Finland, Central Finland Biobank, Northern Finland Biobank Borealis, and 
Finnish Clinical Biobank Tampere) has its own Scientific and Ethical 
Committee that reviewed and approved this study. Detailed patient clinical 
data from the Helsinki University Hospital were collected based on the 
approval of the Surgical Ethics Committee (Dnro 226/E6/2006, extension on 








5.1 RE-EVALUATION OF THE TUMORS (STUDIES I AND 
IV) 
Study I involved 134 tumors from the Helsinki Biobank. Based on histological 
re-evaluation according to the 2015 WHO classification, 30% of the primary 
classifications changed (Figure 11A). Altogether, 13 ACs were reclassified as 
TCs, and 27 TCs were reclassified as ACs. One AC tumor was reclassified as 
small-cell carcinoma (SC CA) and was excluded from the final tumor cohort. 
 
 
Figure 11. Effect of histologic re-evaluation of tumors. One spot represents one tumor. 





A lower proportion of changed classification (21%) was observed when 
evaluating the nationwide tumor cohort in study IV (Figure 11B). Here, 16 ACs 
were reclassified as TCs and 31 TCs were reclassified as ACs. One tumor that 
was primarily classified as neuroendocrine carcinoma (NE CA) was re-
classified as TC. 
5.2 INCIDENCE OF PULMONARY CARCINOID TUMORS IN 
FINLAND (STUDIES I AND IV) 
Study I showed that between January 1990 and December 2012, 13 140 
patients were diagnosed with lung cancer in the Hospital District of Helsinki 
and Uusimaa (HUS), Finland. Of these, PC diagnosis was given to 146 (1.1%) 
patients. The amount of PC tumor resections in the HUS area increased 






In study IV, the nationwide PC tumor incidence was assessed. Between 1990 
and 2016, altogether 62 314 lung cancers were registered by the FCR. Of these, 
1.1% (n=657) were diagnosed as a PC tumor. The age-standardized lung cancer 
incidence decreased during the years from 25.9 to 20.2 per 100 000 persons, 
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Figure 12. Number of resected pulmonary carcinoid tumors in the Hospital 











5.3 CLINICAL, HISTOPATHOLOGICAL, AND SURVIVAL 
DATA OF THE PATIENTS (STUDY IV) 
5.3.1 DEMOGRAPHICS, TUMOR LOCATION AND SIZE, AND SURGICAL 
PROCEDURES 
 
Altogether, 224 patients were included in the study. One hundred and thirty-
seven were females and 87 were males with a median age of 55 years. 
Approximately four out of five tumors were TCs (n=182). The most common 
tumor location was the lower lobe of the right lung (21%). Most of the patients 
(58%) underwent lobectomy. 
The median tumor size, as measured by the pathologist, was 2.0 cm for TCs 
(mean 2.0 cm, range 0.5–5.5 cm) and 1.7 cm for ACs (mean 2.0 cm, range 0.5–
5.0 cm). There was no significant difference in tumor size between the two 
subtypes. Detailed information on demographics, tumor location and size as 
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Figure 13. Lung cancer and pulmonary carcinoid (PC) tumor incidence in Finland 





Table 13. Demographics, tumor location and size, and surgical procedures of the patients. 
AC, atypical carcinoid; TC, typical carcinoid. 
5.3.2 TREATMENT CHARACTERISTICS OF THE PATIENTS 
 
All patients included in this study underwent surgery. Three AC patients 
received neoadjuvant treatment: one was treated with radiotherapy, another 
with chemotherapy, and a third with both radiotherapy and chemotherapy. 
None of the patients received post-operative adjuvant treatment. 
Hilar or mediastinal (N1/N2) nodal involvement was examined 
histopathologically from the surgical specimen in 161 patients (72%). Of them, 
17 patients (11%) had nodal involvement. Nodal involvement was more 
common in AC than in TC patients (8/38 (21%) vs 9/123 (7%), respectively, 






Sex       
male 66 (36%) 21 (50%) 87 (39%) 
female 116 (64%) 21 (50%) 137 (61%) 
Age       
mean 54  54  54  
median 55  56  55  
range 19–86  23–77  19–86  
Location of the tumor       
right lung 111 (61%) 24 (57%) 135 (60%) 
upper lobe 25  9    
middle lobe 35  8    
lower lobe 40  7    
main bronchus 2  0    
two lobes 8  0    
unknown 1  0    
left lung 69 (38%) 18 (43%) 87 (39%) 
upper lobe 34  7    
lower lobe 34  6    
main bronchus 1  3    
unknown 0  2    
unknown 2 (1%) 0  2 (1%) 
Tumor size (cm)       
≤1 46 (25%) 11 (26%) 57 (25%) 
1.1–2.5 91 (50%) 19 (45%) 110 (49%) 
>2.5 42 (23%) 11 (26%) 53 (24%) 
unknown 3 (2%) 1 (2%) 4 (2%) 
Surgical procedure       
lobectomy 90 (58%) 24 (60%) 114 (58%) 
sleeve resection 17 (11%) 8 (20%) 25 (13%) 
segmentectomy 17 (11%) 1 (3%) 18 (9%) 
bilobectomy 13 (8%) 2 (5%) 15 (8%) 
wedge resection 12 (8%) 1 (3%) 13 (7%) 
pneumonectomy 3 (2%) 4 (10%) 7 (4%) 
enucleation 3 (2%) 0  3 (2%) 








the liver and bones at the time of diagnosis, but the primary tumors were still 
removed. During the follow-up, 11 (6%) TC and 9 (21%) AC patients developed 
recurrent disease either in the lungs, liver, bones, brain, ovary, pancreas, or 
adrenal gland. Recurrent disease was more common in AC than in TC patients 
(P=0.001). 
The median time from primary surgery to recurrent disease was 26 months 
(average 53 months, range 7–239 months). Several therapies were applied to 
treat the recurrent disease (Table 14). The most common ones were 
chemotherapy/radiotherapy alone or combined with SSAs and surgical 
removal of the recurrence. 
 
 
Table 14. Treatment of recurrent disease. AC, atypical carcinoid; 
PRRT, peptide receptor radionuclide therapy; SSA, somatostatin 
analogue; TC, typical carcinoid. 
 
 
TC AC All 
Metastases surgery only 4 0 4 
Chemo/radiotherapy only 1 3 4 
SSA only 2 1 3 
SSA+chemo/radiotherapy 1 4 5 
SSA+PRRT 1 1 2 
SSA+PRRT+chemo/radiotherapy 1 1 2 
No treatment, only follow-up 1 1 2 
 
5.3.3 SURVIVAL OF THE PATIENTS 
 
The follow-up time of the patients ranged from <1 year to 28.0 years (median 
11.4 years, mean 12.7 years). Of 224 patients, 47 died during the follow-up. Six 
TC and 8 AC patients died with evidence of recurrent disease, 2 patients died 
from complications after operation of the recurrent tumor, and 31 patients 
died from unrelated causes. The average survival time for the patients who 
died from the disease was 6.8 years (range 1.1–17.4 years). The OS and DSS 










Table 15. Overall survival (OS) and disease-specific survival (DSS) rates of the patients. 
AC, atypical carcinoid; CI, confidence interval; TC, typical carcinoid. 
 
5-year OS  
(95% CI) 
10-year OS  
95% CI) 






94% (90–97%) 86% (81–91%) 97% (94–99%) 95% (91–97%) 
TC 
patients 
96% (91–98%) 89% (83–93%) 99% (96–100%) 98% (94–99%) 
AC 
patients 
88% (73–95%) 74% (57–85%) 90% (76–96%) 81% (63–90%) 
 
 
5.3.4 CLINICAL AND PATHOLOGICAL PROGNOSTIC FACTORS 
 
Five clinical or tumor-related factors were recognized to be prognostic for 
survival (Figure 14). These were age at primary surgery, histologic subtype of 
the tumor, tumor size, presence of lymph node involvement at diagnosis, and 
presence of metastatic disease at diagnosis or during the follow-up. All these 
factors were also identified as potential risk factors for disease-specific 
mortality (Table 16). 
 
Table 16. Analysis of potential risk factors for disease-specific mortality. AC, atypical    
carcinoid; HR, hazard ratio; TC, typical carcinoid. 




Age (>56 vs ≤55) 0.023  4.5 (1.2–16.7) 
Tumor size  
(≥2.5 cm vs <2.5 cm) 
0.045  3.2 (1.0–9.9) 
Histological type  
(AC vs TC) 
<0.001  7.8 (2.5–23.8) 
Hilar/mediastinal lymph node involvement 
at primary surgery (yes vs no) 
<0.001  11.9 (3.6–39.2) 
Presence of metastatic disease 
(yes vs no) 










Figure 14. Disease-specific survival probabilities based on age at primary surgery (A), 
histological subtype of the tumor (B), tumor size (C), presence of lymph node involvement at 
diagnosis (D), and presence of metastatic disease at diagnosis or during the follow-up (E). 







5.4 TUMOR BIOMARKER EXPRESSION 
5.4.1 ACTH, CALCITONIN, SEROTONIN, TTF-1 AND KI-67 EXPRESSION 
IN PULMONARY CARCINOID TUMORS (STUDIES I AND IV) 
 
In study I, 133 PC tumors were labeled immunohistochemically against ACTH, 
calcitonin, serotonin, TTF-1, and Ki-67. ACTH expression was observed in 27 
(21%) tumors whereas 31 (24%) tumors expressed calcitonin and 53 (41%) 
tumors serotonin (Table 17). There was no difference in peptide expression 
between the TCs and ACs, nor was the peptide expression associated with DSS. 
One hundred and three tumors expressed TTF-1. The difference in 
expression between TC and AC tumors was not significant, neither was the 
expression associated with DSS. 
In study I, the median Ki-67 PI was 1% (mean 1.3%, range <1–15%) with 
no difference in the expression level between TCs and ACs. Similar Ki-67 PI 
values were observed in study IV with 224 patients (median 1%, mean 1.6%, 
range <1–18%). No difference in the expression level between TCs and ACs 
was observed here either. Both image analysis methods yielded similar Ki-67 
values. 
In study I, patients with a Ki-67 PI ≥2.5% were shown to have an increased 
risk of shorter DSS compared with those with a Ki-67 PI <2.5% (univariate Cox 
regression: HR 10.5, 95% CI 2.1–52.1, P=0.004). Study IV strengthened this 
finding (univariate Cox regression: HR 11.5, 95% CI 3.7–35.8, P<0.001). 
Survival probabilities based on the Ki-67 PI are presented in Figure 15. 
 
Table 17. Number of tumors expressing ACTH, calcitonin, serotonin, TTF-1, and Ki-67. 
Protein Study TC 
 
 
AC  All  
ACTH I 21 (21%) 6 (18%) 27 (21%) 
Calcitonin I 25 (26%) 6 (18%) 31 (24%) 
Serotonin I 39 (40%) 14 (42%) 53 (41%) 
TTF-1 I 81 (82%) 22 (67%) 103 (78%) 
Ki-67 PI I       
<1%  44 (46%) 10 (30%) 54 (42%) 
1–2%  45 (47%) 18 (55%) 63 (49%) 
>2  7 (7%) 5 (15%) 12 (9%) 
Ki-67 PI IV       
<1%  57 (32%) 11 (26%) 68 (31%) 
1–2%  102 (58%) 21 (50%) 123 (56%) 









5.4.2 SOMATOSTATIN RECEPTOR EXPRESSION IN PULMONARY 
CARCINOID TUMORS (STUDY II) 
 
SSTR1–5 expression was studied in a series of 178 PC tumors. The most 
commonly expressed receptor was SSTR2 (75%), followed by SSTR3 (56%), 
SSTR1 (52%), SSTR5 (32%), and SSTR4 (16%). The only difference in the 
SSTR1–5 expression between TCs and ACs was TCs showing SSTR2 
membranous expression more often than ACs (P=0.007). 
Here, primary tumor sample / metastasis sample pairs were also studied. 
The concordance of the receptor status was 100% for SSTR2 and SSTR4. For 
SSTR5, one metastasis sample was considered positive while the 
corresponding primary tumor was negative (concordance 92%). For SSTR1, 
the same was observed for two primary tumor / metastasis sample pairs 
(concordance 83%). On the contrary, for SSTR3, four metastasis samples were 
negative while the corresponding primary tumors were positive (concordance 
71%). Expression of SSTRs was associated with different clinical, pathological, 







Figure 15. Disease-specific survival probabilities based on the Ki-67 proliferation index in 





Table 18. Association of somatostatin receptor (SSTR) expression with clinical and outcome 
parameters. AC, atypical carcinoid; CI, confidence interval; DSS, disease-specific survival; 





SSTR1 Negativity was associated with metastatic disease (14/81, 
17% vs 4/88, 5%) 
 0.011 
SSTR1 Positivity was associated with improved outcome (HR 0.167, 
95% CI 0.04–0.8) 
 0.021 
SSTR2 Negative tumors were smaller than positive tumors (on 
average 1.6 cm vs. 2.0 cm) 
 0.011 
SSTR2 Negativity was associated with lymph node involvement at 
diagnosis (7/32 (22%) vs 6/102 (6%)) 
 0.014 
SSTR2 Negativity was associated with metastatic disease (9/45, 
20% vs 10/132, 8%) 
 0.027 
SSTR2 Positivity was associated with improved outcome in AC 
patients (HR 0.08, 95% CI 0.01–0.7) 
 0.022 
SSTR3 Positivity was associated with increased risk of shorter DSS 
(HR 4.7, 95% CI 1.0–21.5) 
 0.046 
SSTR4 Positivity was associated with lymph node involvement at 
diagnosis (7/32 (22%) vs 6/102 (6%)) 
 0.017 
 Positivity was associated with metastatic disease (7/28, 25% 
vs 12/149, 8%) 
 0.015 
SSTR4 Positivity was associated with increased risk of shorter DSS 
in AC patients (HR 6.6, 95% CI 1.5–29.6) 
 0.013 
 
5.4.3 PD-1 AND PD-L1 EXPRESSION IN PULMONARY CARCINOID 
TUMORS (STUDY III) 
 
PD-1 and PD-L1 expression was evaluated in 168 PC tumors. PD-1 expression 
was observed in 40% (n=68) of the tumors (median 2, mean 7, range 1–177 
cells per mm2), while high PD-1 expression was seen in 16% (n=27) of the 
tumors. High PD-1 expression was associated with younger age but not with 
clinical or pathological parameters or patient outcome. 
PD-L1 expression was seen in nine TC tumors; all AC tumors were negative 
for PD-L1. In TC patients, PD-L1 expression was associated with lymph node 
involvement at diagnosis (2/5, 40% vs 3/89, 3%, P=0.021) as well as with 
metastatic disease in general (3/9, 33% vs 3/88, 3%, P=0.010). PD-L1 
expression was not associated with patient outcome. 
To evaluate the immunological activity in PC tumors, the density of CD8+ 
tumor infiltrating lymphocytes was calculated. The median CD8+ T-cell 
density was 45 cells per mm2 (mean 74, range 2–823 cells per mm2). CD8+ T-










5.5 PERFORMANCE OF FINNISH BIOBANKS (STUDY IV) 
Finnish hospital-integrated biobanks cover the whole of Finland (Figure 16). 
To evaluate their performance, the PC tumor biobank sample numbers were 
compared with the histologically confirmed PC patient numbers registered by 
the FCR. A 10-year period starting from 2002 was considered. 
During this period, 233 histo-
logically confirmed PC tumor 
patients were registered by the 
FCR from which the biobanks 
identified 206 (88%) tumors from 
their sample registries. Of these 
206 tumors, the biobanks 
delivered to this study 129 tumors 
(63%), of which 12 were excluded 
due to incompatible PC 
morphology, not being primary 
tumors but metastases, or because 
of lack of follow-up data. In the 
end, 117 tumors were included, 
corresponding to 57% of the 
tumors the biobanks primarily 
identified from their sample 
registries. 
The major bottleneck in the 
sample delivery process was the 
slowness of the process. The 
response time from the favorable 
statement of the biobanks’ 
Scientific and Ethical Committees 
to receipt of the samples and data 
varied between 6 and 22 months. 
The most challenging part of the 
biobanks’ work was collecting the 




Figure 16. Finnish hospital-integrated biobanks 
with the population base given in parentheses (as 






This study includes one of the largest PC tumor patient cohorts in recent times. 
All patients were surgically treated, and their primary tumor tissue samples 
were re-evaluated according to the latest WHO classification and processed 
into next-generation TMA format. Tumor samples were coupled with clinical 
and outcome data enabling the comparison between different 




Pulmonary carcinoid tumor incidence, re-evaluation, and clinico-
pathological prognostic factors 
 
According to this study, PC tumors account for 1% of all pulmonary 
malignancies in Finland. From 1990 to 2016, the PC tumor incidence in 
Finland doubled. Both findings are in accordance with the global literature 
(Boyar Cetinkaya et al. 2017; Dasari et al. 2017; Naalsund et al. 2011; 
Skuladottir et al. 2002). 
As TC and AC tumors present different clinical behavior and have different 
prognosis, correct tumor classification is a necessity. All tumors included in 
this study were re-evaluated by expert pulmonary pathologists based on 
morphology and the immunohistochemical staining pattern according to the 
2015 WHO classification. After re-evaluation, the diagnostic group, TC or AC, 
changed in 21% of the tumors. This is mainly explained by the fact that tens of 
general pathologists had provided the primary diagnoses recorded in the 
patient files. In addition, new criteria for the classification of pulmonary NETs 
were implemented in the WHO classification in 1999, and the classification 
was further fine-tuned in 2015 (Travis et al. 1998, 2015b). 
In this patient series, TC tumors were more frequent than AC tumors – four 
out of five tumors were TCs. Female gender was prominent when evaluating 
all PC tumors. This difference has also been reported previously in large 
register-based studies involving more than 1000 PC patients (Filosso et al. 
2015; Hobbins et al. 2016). However, when focusing only on AC tumors, both 
genders were equally represented as also observed by Daddi et al. (2014) and 
Beasley et al. (2000). 
AC tumors presented more often hilar/mediastinal lymph node 
involvement at diagnosis as well as distant metastasis during follow-up than 
TC tumors did. This finding is in line with previous reports (Cusumano et al. 









In our patient series, 5- and 10-year DSS rates for TC patients were 99% and 
98%, respectively, and for AC patients 90% and 81%, respectively. These are 
higher than many of the previously presented rates, which is probably due to 
the fact that this series included only surgically resected patients. In addition, 
in most of the studies overall survival rates are presented instead of DSS rates, 
which naturally affects the rates (Cusumano et al. 2017; Daddi et al. 2014; 
Okereke et al. 2016; Rea et al. 2007; Skuladottir et al. 2002).  
This study showed that age over 56 years, atypical subtype of the tumor, 
presence of lymph node involvement at diagnosis, metastatic disease, tumor 
size over 2.5 cm, and Ki-67 PI over 2.5% were related to disease-specific 
survival in resected PC patients. All these findings have been reported earlier 
with slightly different cut-offs for age, tumor size, and Ki-67 PI (Beasley et al. 
2000; Cao et al. 2011; Clay et al. 2017; Kornerup et al. 2017; Marchevsky et al. 
2018; Rea et al. 2007; Swarts et al. 2017). 
The prognostic impact of lymph node involvement especially in TC patients 
has been under discussion. To address this, Kneuertz et al. (2018) conducted 
a registry-based study including 3335 PC patients (2893 TCs and 442 ACs) 
with 10 or more lymph nodes resected during the primary surgery. They 
observed that lymph node involvement was present in 21% of the patients (17% 
of TC patients and 46% of AC patients) and showed that the 5-year survival 
was significantly worse for patients with lymph node involvement compared 
with patients with a lymph node negative disease. Interestingly, in subgroup 
analysis, lymph node involvement was not associated with a worse survival in 
TC patients whose tumor was <2 cm. In our study, 11% of the patients (7% of 
the TC patients and 26% of the AC patients) presented with lymph node 
involvement at diagnosis. However, only 72% of the patients underwent lymph 
node dissection during the primary surgery.  
Similarly, the significance of the Ki-67 PI as a biomarker to separate 
between TC and AC and as a prognostic factor is under lively research and 
discussion. The Ki-67 PI is currently implemented in the grading of pancreatic 
and gastrointestinal neuroendocrine neoplasms but its usefulness in the 
grading of pulmonary NETs remains uncertain (Rindi et al. 2018). Clay et al. 
(2017) observed that the Ki-67 PI of <5%, 5–9.9%, and ≥10% separates the 
patients into low-risk, intermediate-risk, and high-risk categories in terms of 
relapse-free survival. They also showed that 3.5% is the best Ki-67 cut-off value 
to distinguish AC from TC. On the other hand, Swarts et al. (2017) reported a 
cut-off value of 2.5% (manual counting) or 1% (digital analysis) to separate 
between the patients with a longer overall survival and those with a shorter 
overall survival. However, in multivariate analysis the effect of Ki-67 PI on 
overall survival disappeared. Moreover, Marchevsky et al. (2018) showed that 
TC tumor patients with a Ki-67 PI <5% have a longer overall survival than TC 
tumor patients with a Ki-67 PI ≥5%. According to our study, the Ki-67 PI is not 






Currently, consensus regarding the optimal method to assess the Ki-67 PI in 
PC tumors is lacking. Digital image analysis, manual counting, and eyeball 
estimation yield different results. There is neither consensus on the number of 
cells nor areas (hotspots vs randomly selected areas) to be included in the 
assessment (Swarts et al. 2017). 
 
 
ACTH, calcitonin, serotonin, and TTF-1 as prognostic markers 
 
PC tumors are known to secrete metabolically active peptides or amines. Of 
these, we studied immunohistochemical expression of ACTH, serotonin, and 
calcitonin with the aim to find association between the expression level and 
survival.  
ACTH-secreting PC tumors associated with ectopic Cushing’s syndrome 
were previously considered an aggressive subtype of PC tumor (Boddaert et al. 
2012; Lococo et al. 2016; Shrager et al. 1997). According to the studies, tumors 
were characterized by a high rate of mediastinal lymph node involvement (43-
50%) and increased recurrence rate. However, these studies included a 
relatively small number of patients (n=7–23). A recent study by La Rosa et al. 
(2019) investigated 254 PC tumor samples of which 63 were ACTH positive. 
Of these ACTH positive tumors, 11 were functional and associated with 
Cushing’s syndrome. La Rosa et al. showed that neither ACTH production, as 
measured by immunohistochemistry, nor Cushing’s syndrome due to ectopic 
ACTH production were associated with tumor recurrence or patient outcome. 
However, La Rosa et al. also reported more lymph node metastases in patients 
with Cushing’s syndrome compared with patients with non-functioning ACTH 
positive tumor (55% vs 10%, respectively). In our series, ACTH expression was 
not associated with survival either. 
We were not able to find previous studies on the association of calcitonin 
or serotonin expression with patient outcome. Instead, Ianniello et al. (2016) 
reported TTF-1 negativity to be associated with longer median PFS in TC 
patients treated with PRRT (26.3 months for TTF-1 negative patients vs 7.2 
months for TTF-1 positive patients). Unfortunately, they did not describe, 
which primary antibody was used for labeling TTF-1. As shown by La Rosa et 
al. (2010) and Matoso et al. (2010), different clones have different sensitivity, 
and the SPT24 clone seems to be more sensitive for labeling PC tumors. 
However, with this clone, we were not able to show any differences in patient 
outcome between TTF-1 negative and TTF-1 positive patients. 
 
 
Somatostatin receptor expression in pulmonary carcinoid tumors 
 
According to the treatment guidelines, the primary therapy for PC tumor is 
surgery, while SSAs are a treatment option in inoperable or metastatic disease 








NET patients – octreotide and lanreotide – bind preferentially to SSTR2 but 
also to a lesser extent to SSTR3 and SSTR5 (Reubi & Schonbrunn 2013). In 
contrast, pasireotide, currently under phase II studies, has affinity to SSTR5 
and SSTR1–3.   
In this tumor material, the only difference in SSTR expression between TC 
and AC tumors was seen for SSTR2 – TC tumors more often showed 
membranous staining than AC tumors did. Interestingly, this study showed 
that metastases result in a similar SSTR staining pattern to their 
corresponding primary tumors. This suggests that the SSTR profile in 
metastases can be used for treatment decision-making if a tissue sample from 
the primary tumor is not available. 
According to this study, lack of SSTR2 expression and the presence of 
SSTR4 expression were associated with lymph node involvement and distant 
metastasis. In addition, lack of SSTR1 expression was associated with distant 
metastasis. These were all novel findings that may give a hint of the tumor’s 
aggressive behavior, warranting a more careful follow-up of these patients. In 
contrast, Kanakis et al. (2015) and Righi et al. (2010) found no association 
between SSTR expression and metastatic disease in their patient series. 
However, they used mainly polyclonal primary antibodies as well as slightly 
different scoring criteria. In addition, while Kanakis’s patient series (n=106) 
was clinically similar to ours, Righi et al. studied patients with clinically 
aggressive disease, in other words TC patients who had metastatic disease at 
the time of diagnosis (n=24) or AC patients (n=73).    
In our tumor material, SSTR1–4 had prognostic value. When evaluating all 
patients, lack of SSTR1 expression and presence of SSTR3 expression were 
associated with shorter DSS. Similarly, lack of SSTR2 expression and presence 
of SSTR4 expression were associated with a higher risk of disease-specific 
mortality in AC patients. Kaemmerer et al. (2015) reported the same for SSTR1 
– PC patients whose tumor had a high SSTR1 expression had better outcome. 
In contrast, they found no association between the other receptors and 
outcome. Daskalakis et al. (2018) did not observe any prognostic value of 
SSTR1-5 expression for overall or event-free survival in PC patients. 
The lack of SSTR2 seems to be a sign of an aggressive tumor that requires 
close follow-up to observe metastatic disease as early as possible. The 
challenge is that currently approved SSAs for imaging and treatment bind 
preferably to SSTR2. In our study, approximately one fifth of the PC tumors 
were SSTR2 negative but at the same time presented especially SSTR3 and 
SSTR4. These patients are likely to benefit from multi-receptor targeting SSAs, 
such as KE108 and somatoprim, currently under development, that have high 
affinity for SSRT3 and SSTR4 (Reubi & Schonbrunn 2013, Chen et al. 2016, 









PD-1 and PD-L1 expression in pulmonary carcinoid tumors 
 
Whereas there has been successful development of targeted therapies for lung 
adenocarcinomas, squamous cell carcinomas, and small-cell carcinomas, very 
little progress has been achieved for PC tumors beyond targeting SSTRs with 
SSAs. Since immune checkpoint inhibitor-based therapy targeting PD-1 and 
PD-L1 has shown promising efficacy in other malignancies like melanoma and 
NSCLC, this study aimed to evaluate PD-1 and PD-L1 expression in PC tumors 
as potential treatment targets and as prognostic markers. 
In this tumor material, the median number of PD-1 positive intratumoral 
lymphocytes was low, 2 per mm2, indicating that these tumors are 
immunologically “cold”. PD-L1 expression was observed only in nine tumors 
(5%), all being TC tumors. No association between PD-1 or PD-L1 expression 
and patient outcome was found, but PD-L1 expression in TC tumors was 
associated with metastatic disease. This was a novel finding since previous 
studies reported a lack of association with metastasis (Fan et al. 2016; Wang 
et al. 2018). However, both studies merged PC tumors with high-grade 
neuroendocrine malignancies and analyzed them together, which might have 
affected the results. They also used different primary antibodies and partly 
different scoring criteria than we did. 
Different primary antibodies and scoring criteria are indeed also a clinical 
challenge. PD-L1 immunohistochemistry is used to aid clinicians in treatment 
decision-making since some of the drugs are only prescribed to patients whose 
tumor shows PD-L1 expression. Currently, there are four different PD-1 or PD-
L1 targeting drugs available for the treatment of NSCLC patients (nivolumab, 
pembrolizumab, atezolizumab, and durvalumab) and all of them are linked to 
a separate immunohistochemical PD-L1 assay (Koomen et al. 2019). These 
assays have a different clone of the PD-L1 antibody (28-8, 22C3, SP142, and 
SP263) as well as a different staining platform (Dako or Ventana/Roche) and 
partly different scoring criteria. In addition to these standardized assays, 
laboratory-developed tests may also be used as we did when using the PD-L1 
clone E1L3N. According to a recent systematic review, good correlation exists 
between E1L3N and assays for SP263, 28-8, and 22C3, while SP142 showed 
lower concordance values (Koomen et al. 2019).   
Immunotherapy with antibodies targeting PD-1 or PD-L1 is not included 
in the current treatment guidelines for PC patients. Two clinical trials have 
shown that anti-PD-1 monotherapy with pembrolizumab is beneficial to a 
small subset of NET patients, including PC patients. KEYNOTE-028 enrolled 
patients whose tumor expressed PD-L1 (Mehnert et al. 2017). Of the enrolled 
41 patients, 10% had an objective response. On the other hand, KEYNOTE-158 
enrolled 107 patients irrespective of PD-L1 status (Strosberg et al. 2019). In 
their study, the overall response rate was less than 4%. Interestingly, all four 
responders had a PD-L1 negative tumor. While PD-1 or PD-L1 targeting 








are included in the NCCN treatment guidelines for advanced cutaneous 
neuroendocrine neoplasia, Merkel cell carcinoma (Bichakjian et al. 2018).   
One of the challenges in treating patients with antibodies targeting the PD-
1/PD-L1 pathway is the selection of suitable patients. Currently, PD-L1 
expression in the tumor is the best-known biomarker for selection, but based 
on the above-mentioned studies, it does not seem to be the optimal one for 
NET patients. Thus, new predictive biomarkers are urgently needed. Tumor 
mutational burden (TMB), as measured with next-generation sequencing as 
mutations per megabase, is proposed to be such a marker in other cancer types 
like NSCLC and melanoma (Goodman et al. 2017). Reports on TMB as a 




Performance of Finnish biobanks 
 
As PC tumors are relatively infrequent malignancies with a generally indolent 
nature, collecting study material is challenging. Most of the tumors are TCs 
which are mainly cured by surgery. More aggressive ACs that may develop 
recurrence or metastasis represent a minority of all PC patients. Thus, focusing 
on this patient entity requires a geographically large catchment area or 
recruitment from centers specialized in treating PC patients. Here, Finnish 
hospital-integrated biobanks were a valuable source of study material. 
Collecting samples and data for medical research purposes has a long 
tradition in Finland. Traditional collection for the needs of a single research 
project based on a favorable statement from an ethical committee is still 
ongoing, although biobanks are taking more responsibility for sample 
management nationwide. From an ethical point of view, biobanks need to 
ensure that biospecimens collected from the consenting participants are used 
appropriately for medical research. Underutilization of biospecimens is of 
both ethical and practical concern. Here, biospecimen quality and fit for the 
intended purpose are important factors as well as simple biospecimen access 
policies and marketing communication. 
Currently, Finnish hospital-integrated biobanks include clinical pathology 
tissue archives that were available before September 1, 2013. This was the date 
when the Biobank Act came into force and set the latest collection date for the 
samples to be transferred into a biobank. Now, 6 years later, this restriction is 
still valid and prevents accessing of the samples collected after August 31, 2013 
unless the patient had given a biobank consent. Unfortunately, most hospital-
integrated biobanks did not start to gain consent from patients on a large scale 
until 2016, leading to a gap in tissue sample access. To address this issue, 
among other things, the Biobank Act is under reform and the proposed version 
offers an opt-out procedure for using the samples derived from patient care in 
biobank studies. More importantly, the reform aims to make the necessary 





Regulation as well as from the law interpretation challenges recognized by the 
Steering Group of the Biobank Act. The proposed reformed law is also linked 
to the Act on Secondary Use of Social and Health Information as well as to the 
proposed Genome Act. 
Despite the gap in tissue sample access between September 2013 and the 
present moment, Finnish hospital-integrated biobanks administer a 
remarkable amount of tissue samples. Between 2002 and 2011, the biobanks 
identified 206 primary PC tumor tissue samples from their registries, which 
corresponds to 88% of the histologically verified PC tumors registered by the 
FCR. Unfortunately, one third of the tissue samples could not be found from 
the biobank archives or they were too scarce to be used for research. The most 
feasible explanation for missing samples is the use of them in research projects 
before the biobank era when the sample usage was not always appropriately 
registered or followed up. To clarify, the transfer of millions of clinical 
pathology tissue samples into biobanks was based on the registry data, and no 
physical checking of sample availability was performed.  
Altogether 224 PC tumor samples were retrieved from the biobanks. Nearly 
60% of them were from the Helsinki Biobank even though its sphere of 
operations covers less than 40% of the Finnish population. However, Helsinki 
University Hospital serves as a reference center for treating PC patients which 
explains the difference between the expected number of patients based on the 
size of the population and the actual patient number. 
The major challenge in sample and data access was the slowness of the 
process, especially in harvesting the clinical data. An obvious reason for this 
was that our sample and data proposals were among the first ones and all 
policies in the biobanks were not yet optimized. However, clinical data 
collection in biobanks remains a challenge. The amount of patient medical 
data in different hospital records is huge and heterogeneous and mostly in the 
form of free text, not structured or in standardized format. This poses 
difficulties for automatic data mining. In Finland, electronic medical records 
have been utilized nationwide over two decades. Unfortunately, the 
development of the health information system has been largely uncoordinated 
at the national level leading to non-interoperable information systems. 
Moreover, several incompatible applications are utilized even within a single 
health-care organization. Thus, local and regional quality registers have been 
developed. These registers contain information, for example, on the treatment 
of patients and the treatment responses. Currently, THL is leading a project 
which aims to create a model for national quality registers with unified data 
contents (THL 2019). Based on the Act on Secondary Use of Social and Health 
Information, these registers can also be utilized for scientific research in the 
future.   
Then again, biobanks presented excellent facilities and technical skills in 
processing the FFPE tissue samples into TMA format. As no TMA block is 
delivered to the researchers, only unstained sections, and as duplicate blocks 








future research projects. Also, digitized images of our immunohistochemical 
stains coupled with staining protocols and tumor-specific analysis data will be 
returned to the biobanks to be part of their data collections. These data can be 
later delivered to other research projects. 
 
Strengths and limitations of the study 
 
The major strength of this study is a large number of clinically well-
characterized patients coupled with a tumor sample and exact survival and 
cause of death data. Each tumor was appropriately re-evaluated according to 
the latest WHO classification criteria. Clinically validated protocols for 
immunohistochemical stains were utilized in 75% (12/16) of the stains. 
Using TMA sections instead of whole sections is both a strength and a 
limitation. It is true that some positive areas for different antigens might have 
been missed despite a comprehensive next-generation TMA approach with 
punches retrieved from both the middle of the tumor and from the tumor 
border. On the other hand, a whole section still represents only a part of the 
removed tumor. Using TMA sections, at least all tumor tissue was labeled 
immunohistochemically under similar conditions.  
TMA seems to be a suitable method for studying biomarkers that are evenly 
expressed in tumor tissue, such as chrom A and SYP. For biomarkers that are 
expressed more heterogeneously, a whole section approach would be more 
suitable. In both cases, TMA is an appropriate method for screening different 
biomarkers.     
Despite a relatively long follow-up of the patients, only a limited number of 
disease-specific deaths were observed. Due to this, no multivariate analysis in 
terms of risk ratio of different variables to patient outcome could be performed. 
As this study was retrospective dating back to the 1990s, lymph node 
dissection was not performed in all patients, resulting in a potential 
misclassification of locally advanced disease. Similarly, SSTR imaging data 
were not available to be compared with the immunohistochemical SSTR 
expression. Immunohistochemistry itself also contains several methodological 
and technical possibilities for error. Even if clinically validated protocols were 
utilized, the steps before that, for example ischemia time and fixation of the 
tumor specimen, could not be controlled. In addition, analyzing staining 
results is at least to some extent subjective and intra- and interobserver 
variation occurs. Understandably, there are high hopes that the ever-evolving 





Currently, there is no biomarker that can differentiate between TC and AC, but 
the categorization is based on morphology. Similarly, there is a lack of 





protocol and treatment of an individual patient. As our understanding of the 
genetic background of PC tumors evolves, these needs might be met. One 
recently identified potential predictive marker and therapeutic target is delta-
like protein 3, an inhibitory ligand of the Notch signaling pathway. More 
markers and targets will hopefully be discovered as gene-expression studies 
are conducted with larger PC tumor series. 
At the Finnish scale, a national registry of PC tumor patients with 
comprehensive fresh tissue and blood sampling through the biobanking 
infrastructure could form a valuable resource for research in the future. Also, 
PC tumor samples collected in the clinical pathology laboratories after the 
Biobank Act came into force should become accessible via biobanks. In 
particular, AC tumor samples and aggressive TC tumor samples are urgently 
needed. Moreover, structured and standardized patient medical data in 
hospital records would accelerate especially data collection accomplished in 
the biobanks. 
This study utilized only Finnish biobanks, but in the future, international 
biobanks will be taken into account. At least Swedish U-CAN is known to store 
tissue samples and clinical data from PC tumor patients. Other sources of 
patient material will be identified from, for example, the BBMRI-ERIC 










The main conclusion of this thesis is that the Ki-67 PI, SSTR expression profile, 
and PD-L1 expression are potential predictive or prognostic biomarkers in PC 
tumors. However, larger studies are needed to validate the results.  
 
The specific conclusions of this thesis are: 
 
1. Resected PC tumor patients are generally characterized by favorable 
long-term survival. Age over 56 years at diagnosis, tumor size over 2.5 
cm, atypical subtype, Ki-67 PI higher than 2.5%, hilar/mediastinal lymph 
node involvement at diagnosis, and presence of metastatic disease are 
associated with worse outcome. Serotonin, ACTH, calcitonin, and TTF-1 
expression add no prognostic value. 
 
2. Lack of SSTR1 or SSTR2 expression and presence of SSTR4 expression 
are associated with metastatic disease. Lack of SSTR1 and presence of 
SSTR3 expression are risk factors for disease-specific death in PC tumor 
patients. The same applies to the lack of SSTR2 expression and presence 
of SSTR4 expression in AC tumor patients. 
 
3. A limited number of PD-1 positive intratumoral lymphocytes are present 
in PC tumor tissue, and only a minority of PC tumors express PD-L1. 
Thus, monotherapy with anti-PD-1/PD-L1 might benefit only a subset of 
PC tumor patients. However, PD-L1 expression shows prognostic value 
as it is associated with metastatic disease. 
 
4. Finnish biobank infrastructure offers excellent facilities for medical 
tissue-based research. To further develop the processes, involving more 
medical knowledge in the sample and data distribution process is crucial. 
Also, when working with tissue samples collected over decades, re-













This thesis work was carried out at the Department of Pathology, University of 
Helsinki and Helsinki University Hospital, between 2016 and 2019. I wish to 
thank Professors Tom Böhling and Olli Carpén for providing excellent facilities 
for research. I also acknowledge the former and the present Head of the 
HUSLAB Pathology, Docent Kaisa Salmenkivi and Docent Päivi Heikkilä, 
respectively, for having a positive attitude towards research work. 
I would like to thank the Doctoral School in Health Sciences for arranging 
excellent courses as well as for financial support during my studies. My sincere 
appreciation goes to the Finnish Cancer Foundation and the Helsinki 
University Hospital research fund for research grants that made this project 
possible. 
I wish to express my sincere gratitude to my excellent supervisors Professor 
Johanna Arola and Professor Caj Haglund. It has been a privilege to work with 
you and learn from you. Johanna, thank you for asking me about my 5-year 
career plan in Bern in 2016. Something special started there, both scientifically 
and in the other fields of life. I admire your attitude as well as huge knowledge 
and commitment to research work. Caj, thank you for your enormous support 
and positive mental attitude. I will archive our latest manuscript with “Super!” 
written on your handwriting. It was a real pleasure to conduct this project 
under the supervision of both of you and I eagerly await our future projects 
together. 
I would like to thank my thesis committee members Professor Marjukka 
Myllärniemi and Professor Leo Niskanen for encouraging discussions during 
the project. Thank you for your feedback. My sincere appreciation goes to the 
reviewers of this thesis, Docent Saila Kauppila and Emerita Professor Pirkko-
Liisa Kellokumpu-Lehtinen. Thank you for your dedicated and thorough 
review of this thesis as well as providing constructive and positive feedback. 
Your valuable comments improved this thesis substantially. Thank you, 
Docent Tarja Laitinen, for accepting the honorable task of being my opponent. 
All my co-authors receive my most profound gratitude. In particular, I 
thank Kaisa Salmenkivi for re-evaluating all tumors, Harri Mustonen for his 
statistical expertise, and Aija Knuuttila for her first-rate clinical expertise. 
Thank you for your time, I learned a lot from you. Teijo Kuopio and Maarit 
Ahtiainen I acknowledge for scoring immunohistochemical stains within a 
busy schedule. Thank you, Sanna Mononen, for collecting clinical data for this 
study. Luckily, I was also privileged to learn from the best – thank you Helena 
Leijon for both histologic expertise and knowledge of technical issues in the 
thesis project that you shared with me. Finnish biobank pathologists Olli 
Carpén, Paula Vainio, Timo Paavonen, Teijo Kuopio, and Elisa Lappi-Blanco I 






Moreover, I warmly acknowledge all Finnish hospital-integrated biobanks for 
providing samples and data for this study. 
I wish to express special thanks to Jenni Niinimäki whose excellent 
technical skills and dedication to deliver only prime-quality TMA sections 
were crucial for this study. Likewise, I thank Eija Heiliö for her first-rate 
performance in staining the valuable sections as well as taking care of many 
practical issues. Many sections were also stained at HUSLAB, Department of 
Pathology. Thank you Mia Kero, Satu Remes, and Reija Randen-Brady 
together with all the technicians for excellent co-operation. 
This journey wouldn’t have been the same without the support of my family, 
relatives, and friends. I wish to express my deepest gratitude to my parents, 
whose support has been tremendous in many ways during my whole life. Kiitos 
äiti ja isä, olette niin rakkaita. I sincerely thank my dear little sister Minna for 
all the encouragement she gave as well as for keeping my back and shoulders 
mobile and strong during the writing process. My godparents, Riitta and Jukka, 
thank you for your support and all kind words. My grandmother, Mummi, is 
not here anymore but I am convinced she is now very proud of me. Thank you 
Mummi for the time we spent together. 
My best friends Mira, Katja, Kati, and Jenni – what would my life be 
without you? Thank you Mira for everything. You have always been there for 
me and reminded me that I can do anything. Thank you also for taking care of 
my dear Atte. Katja, Kati, and Jenni – we have been friends for over three 
decades. Thank you for the beautiful memories we have created together as 
well as your love and care. I also want to thank Reija, Kaisa, Tapio, Maria, 
Minna, Susanna, Tiina, Sirpa, Jari, Maija, Kerstin, Samuli, Mikke, and Iiro for 
unforgettable moments during the years both in Southern and Northern 
Finland as well as abroad. You are the light and joy of my life and keep 
reminding me of the value of true friendship. Now, let’s dance! 
 
 










Alcala, N., Leblay, N., Gabriel, A. A. G., Mangiante, L., Hervas, D., Giffon, T., 
Sertier, A. S., Ferrari, A., Derks, J., Ghantous, A., Delhomme, T. M., 
Chabrier, A., Cuenin, C., Abedi-Ardekani, B., Boland, A., Olaso, R., 
Meyer, V., Altmuller, J., Le Calvez-Kelm, F., Durand, G., Voegele, C., 
Boyault, S., Moonen, L., Lemaitre, N., Lorimier, P., Toffart, A. C., 
Soltermann, A., Clement, J. H., Saenger, J., Field, J. K., Brevet, M., 
Blanc-Fournier, C., Galateau-Salle, F., Le Stang, N., Russell, P. A., 
Wright, G., Sozzi, G., Pastorino, U., Lacomme, S., Vignaud, J. M., 
Hofman, V., Hofman, P., Brustugun, O. T., Lund-Iversen, M., Thomas 
de Montpreville, V., Muscarella, L. A., Graziano, P., Popper, H., Stojsic, 
J., Deleuze, J. F., Herceg, Z., Viari, A., Nuernberg, P., Pelosi, G., 
Dingemans, A. M. C., Milione, M., Roz, L., Brcic, L., Volante, M., 
Papotti, M. G., Caux, C., Sandoval, J., Hernandez-Vargas, H., 
Brambilla, E., Speel, E. J. M., Girard, N., Lantuejoul, S., McKay, J. D., 
Foll, M., Fernandez-Cuesta, L. Integrative and comparative genomic 
analyses identify clinically relevant pulmonary carcinoid groups and 
unveil the supra-carcinoids. Nat Commun 10(1):3407, 2019. 
Armengol, G., Sarhadi, V. K., Ronty, M., Tikkanen, M., Knuuttila, A., Knuutila, 
S. Driver gene mutations of non-small-cell lung cancer are rare in 
primary carcinoids of the lung: NGS study by ion Torrent. Lung 
193(2):303-308, 2015. 
Aron, M., Kapila, K., Verma, K. Carcinoid tumors of the lung: a diagnostic 
challenge in bronchial washings. Diagn Cytopathol 30(1):62–66, 2004. 
Arrigoni, M. G., Woolner, L. B., Bernatz, P. E. Atypical carcinoid tumors of the 
lung. J Thorac Cardiovasc Surg 64(3):413–421, 1972. 
Aubry, M. C., Thomas, C. F., Jr., Jett, J. R., Swensen, S. J., Myers, J. L. 
Significance of multiple carcinoid tumors and tumorlets in surgical 
lung specimens: analysis of 28 patients. Chest 131(6):1635–1643, 2007. 
Aydin, E., Yazici, U., Gulgosteren, M., Agackiran, Y., Kaya, S., Gulhan, E., 
Tastepe, I., Karaoglanoglu, N. Long-term outcomes and prognostic 
factors of patients with surgically treated pulmonary carcinoid: our 
institutional experience with 104 patients. Eur J Cardiothorac Surg 
39(4):549–554, 2011. 
Bankhead, P., Loughrey, M. B., Fernandez, J. A., Dombrowski, Y., McArt, D. 
G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. 
G., James, J. A., Salto-Tellez, M., Hamilton, P. W. QuPath: Open source 
software for digital pathology image analysis. Sci Rep 7(1):16878, 2017. 
BBMRI.fi web page, accessed in September 2019. http://www.bbmri.fi.  
Beasley, M. B., Thunnissen, F. B., Brambilla, E., Hasleton, P., Steele, R., 
Hammar, S. P., Colby, T. V., Sheppard, M., Shimosato, Y., Koss, M. N., 
Falk, R., Travis, W. D. Pulmonary atypical carcinoid: predictors of 






Beasley, M. B., Brambilla, E., Travis, W. D. The 2004 World Health 
Organization classification of lung tumors. Semin Roentgenol 
40(2):90–97, 2005. 
Biancosino, C., Kruger, M., Vollmer, E., Welker, L. Intraoperative fine needle 
aspirations - diagnosis and typing of lung cancer in small biopsies: 
challenges and limitations. Diagn Pathol 11(1):59, 2016. 
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, 
R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., Farma, 
J. M., Fisher, K., Gastman, B., Ghosh, K., Grekin, R.C., Grossman, K., 
Ho, A. L., Lewis, K. D., Loss, M., Lydiatt, D. D., Messina, J., Nehal, K. 
S., Nghiem, P., Puzanov, I., Schmults, C. D., Shaha, A. R., Thomas, V., 
Xu, Y. G., Zic, J. A., Hoffmann, K. G., Engh, A. M. Merkel Cell 
Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in 
Oncology. J Natl Compr Canc Netw 16(6):742–774, 2018. 
Bini, A., Brandolini, J., Cassanelli, N., Davoli, F., Dolci, G., Sellitri, F., Stella, 
F. Typical and atypical pulmonary carcinoids: our institutional 
experience. Interact Cardiovasc Thorac Surg 7(3):415–418, 2008. 
Biobank Act 2012. Retrieved from 
http://www.finlex.fi/en/laki/kaannokset/2012/en20120688.pdf 
Biobank Graz web page, accessed in September 2019. 
https://www.medunigraz.at/biobank. 
Blood Service Biobank web page, accessed in September 2019. 
https://www.bloodservice.fi/Research%20Projects/biobanking.  
Boddaert, G., Grand, B., Le Pimpec-Barthes, F., Cazes, A., Bertagna, X., 
Riquet, M. Bronchial carcinoid tumors causing Cushing's syndrome: 
more aggressive behavior and the need for early diagnosis. Ann Thorac 
Surg 94(6):1823–1829, 2012. 
Bongiovanni, A., Recine, F., Riva, N., Foca, F., Liverani, C., Mercatali, L., 
Nicolini, S., Pieri, F., Amadori, D., Ibrahim, T. Outcome analysis of 
firstline somatostatin analog treatment in metastatic pulmonary 
neuroendocrine tumors and prognostic significance of 18FDG-PET/CT. 
Clin Lung Cancer 18(4):415–420, 2017. 
Boyar Cetinkaya, R., Aagnes, B., Thiis-Evensen, E., Tretli, S., Bergestuen, D. 
S., Hansen, S. Trends in incidence of neuroendocrine neoplasms in 
Norway: a report of 16,075 cases from 1993 through 2010. 
Neuroendocrinology 104(1):1–10, 2017. 
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., 
Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., 
Krenning, E. P., Kwekkeboom, D. J. Long-term efficacy, survival, and 
safety of [177Lu-DOTA0, Tyr3]octreotate in patients with 
gastroenteropancreatic and bronchial neuroendocrine tumors. Clin 
Cancer Res 23(16):4617–4624, 2017. 
Brierley, J., Gospodarowicz, M. K., Wittekind, C. (editors). TNM classification 
of malignant tumours, 8th edition. Wiley-Blackwell, Chichester, West 
Sussex, UK, 2017. Pages 110–115. 
Canizares, M. A., Matilla, J. M., Cueto, A., Algar, J., Muguruza, I., Moreno-
Mata, N., Moreno-Balsalobre, R., Guijarro, R., Arrabal, R., Garcia-
Fontan, E., Gonzalez-Pineiro, A., Garcia-Yuste, M. Atypical carcinoid 
tumours of the lung: prognostic factors and patterns of recurrence. 





Cao, C., Yan, T. D., Kennedy, C., Hendel, N., Bannon, P. G., McCaughan, B. C. 
Bronchopulmonary carcinoid tumors: long-term outcomes after 
resection. Ann Thorac Surg 91(2):339–343, 2011. 
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, 
E.,  Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., Rindi, G., Langley, 
A., Martinez, S., Blumberg, J., Ruszniewski, P. CLARINET 
Investigators. Lanreotide in metastatic enteropancreatic 
neuroendocrine tumors. N Engl J Med 371(3):224–233, 2014. 
Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., 
Oberg, K., Pelosi, G., Perren, A., Rossi, R. E., Travis, W. D. Pulmonary 
neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor 
Society expert consensus and recommendations for best practice for 
typical and atypical pulmonary carcinoids. Ann Oncol 26(8):1604–
1620, 2015. 
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, 
E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., Rindi, G., Langley, 
A., Martinez, S., Gomez-Panzani, E., Ruszniewski, P.; CLARINET 
Investigators. Anti-tumour effects of lanreotide for pancreatic and 
intestinal neuroendocrine tumours: the CLARINET open-label 
extension study. Endocr Relat Cancer 23(3):191–199, 2016. 
Chen, G., Jaskula-Sztul, R., Harrison, A., Dammalapati, A., Xu, W., Cheng, Y., 
Chen, H., Gong, S. KE108-conjugated unimolecular micelles loaded 
with a novel HDAC inhibitor thailandepsin-A for targeted 
neuroendocrine cancer therapy. Biomaterials 97:22–33, 2016. 
Clay, V., Papaxoinis, G., Sanderson, B., Valle, J. W., Howell, M., Lamarca, A., 
Krysiak, P., Bishop, P., Nonaka, D., Mansoor, W. Evaluation of 
diagnostic and prognostic significance of Ki-67 index in pulmonary 
carcinoid tumours. Clin Transl Oncol 19(5):579–586, 2017. 
Clin, B., Andujar, P., Abd Al Samad, I., Azpitarte, C., Le Pimpec-Barthes, F., 
Billon-Galland, M. A., Danel, C., Galateau-Salle, F., Housset, B., 
Legrand-Cattan, K., Matrat, M., Monnet, I., Riquet, M., Pairon, J. C. 
Pulmonary carcinoid tumors and asbestos exposure. Ann Occup Hyg 
56(7):789–795, 2012. 
ClinicalTrials.gov, U.S. National Library of Medicine web page, accessed in 
December 2019. https://clinicaltrials.gov. 
Corrin, B., Nicholson, A. G. (editors). Pathology of the lungs, 3rd edition. 
Churchill Livingstone, Edinburgh, UK, 2011. Pages 1–37. 
Cusumano, G., Fournel, L., Strano, S., Damotte, D., Charpentier, M. C., Galia, 
A., Terminella, A., Nicolosi, M., Regnard, J. F., Alifano, M. Surgical 
resection for pulmonary carcinoid: long-term results of multicentric 
study - the importance of pathological N status, more than we thought. 
Lung 195(6):789–798, 2017. 
Daddi, N., Schiavon, M., Filosso, P. L., Cardillo, G., Ambrogi, M. C., De Palma, 
A., Luzzi, L., Bandiera, A., Casali, C., Ruffato, A., De Angelis, V., 
Andriolo, L. G., Guerrera, F., Carleo, F., Davini, F., Urbani, M., Mattioli, 
S., Morandi, U., Zannini, P., Gotti, G., Loizzi, M., Puma, F., Mussi, A., 
Ricci, A., Oliaro, A., Rea, F. Prognostic factors in a multicentre study of 







Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., Yao, J. 
C. Trends in the incidence, prevalence, and survival outcomes in 
patients with neuroendocrine tumors in the United States. JAMA Oncol 
3(10):1335–1342, 2017. 
Daskalakis, K., Kaltsas, G., Oberg, K., Tsolakis, A. V. Lung carcinoids: long-
term surgical results and the lack of prognostic value of somatostatin 
receptors and other novel immunohistochemical markers. 
Neuroendocrinology 107(4):355–365, 2018. 
de Laat, J. M., Pieterman, C. R., van den Broek, M. F., Twisk, J. W., Hermus, 
A. R., Dekkers, O. M., de Herder, W. W., van der Horst-Schrivers, A. N., 
Drent, M. L., Bisschop, P. H., Havekes, B., Vriens, M. R., Valk, G. D. 
Natural course and survival of neuroendocrine tumors of thymus and 
lung in MEN1 patients. J Clin Endocrinol Metab 99(9):3325–3333, 
2014. 
den Bakker, M. A., Thunnissen, F. B. Neuroendocrine tumours – challenges in 
the diagnosis and classification of pulmonary neuroendocrine tumours. 
J Clin Pathol 66(10):862–869, 2013. 
Devlin, T.M. (editor). Textbook of Biochemistry with Clinical Correlations, 7th 
edition. John Wiley & Sons, New Jersey, USA, 2010. Pages 181–337. 
Dincer, H. E., Podgaetz, E., Andrade, R. S. Pulmonary neuroendocrine tumors: 
Part I. Spectrum and characteristics of tumors. J Bronchology Interv 
Pulmonol 22(3):267–273, 2015. 
Dixon, R. K., Britt, E. J., Netzer, G. A., Afshar, M., Burke, A., Liu, S., Jean, J., 
Shah, N. G. Ten-year single center experience of pulmonary carcinoid 
tumors and diagnostic yield of bronchoscopic biopsy. Lung 
194(6):905–910, 2016. 
El Jamal, M., Nicholson, A. G., Goldstraw, P. The feasibility of conservative 
resection for carcinoid tumours: is pneumonectomy ever necessary for 
uncomplicated cases? Eur J Cardiothorac Surg 18(3):301–306, 2000. 
Elston, M. S., Meyer-Rochow, G. Y., Conaglen, H. M., Clarkson, A., Clifton-
Bligh, R. J., Conaglen, J. V., Gill, A. J. Increased SSTR2A and SSTR3 
expression in succinate dehydrogenase-deficient pheochromocytomas 
and paragangliomas. Hum Pathol 46(3):390–396, 2015. 
Fainstein Day, P., Frohman, L., Garcia Rivello, H., Reubi, J. C., Sevlever, G., 
Glerean, M., Fernandez Gianotti, T., Pietrani, M., Rabadan, A., 
Racioppi, S., Bidlingmaier, M. Ectopic growth hormone-releasing 
hormone secretion by a metastatic bronchial carcinoid tumor: a case 
with a non hypophysial intracranial tumor that shrank during long 
acting octreotide treatment. Pituitary 10(3):311–319, 2007. 
Fan, Y., Ma, K., Wang, C., Ning, J., Hu, Y., Dong, D., Dong, X., Geng, Q., Li, E., 
Wu, Y. Prognostic value of PD-L1 and PD-1 expression in pulmonary 
neuroendocrine tumors. Onco Targets Ther 9:6075–6082, 2016. 
Fazio, N., Granberg, D., Grossman, A., Saletan, S., Klimovsky, J., 
Panneerselvam, A., Wolin, E. M. Everolimus plus octreotide long-acting 
repeatable in patients with advanced lung neuroendocrine tumors 
analysis of the phase 3, randomized, placebo-controlled RADIANT-2 







Fazio, N., Buzzoni, R., Delle Fave, G., Tesselaar, M., Wolin, E., Van Cutsem, 
E., Tomassetti, P., Strosberg, J., Voi, M., Bubuteishvili-Pacaud, L., 
Ridolfi, A., Herbst, F., Tomasek, J., Singh, S., Pavel, M., Kulke, M. H., 
Valle, J. W., Yao, J. C. Everolimus in advanced, progressive, well-
differentiated, non-functional neuroendocrine tumors: RADIANT-4 
lung subgroup analysis. Cancer Sci 109(1):174–181, 2018. 
Ferolla, P., Brizzi, M. P., Meyer, T., Mansoor, W., Mazieres, J., Do Cao, C., 
Léna, H., Berruti, A., Damiano, V., Buikhuisen, W., Grønbæk, H., 
Lombard-Bohas, C., Grohé, C., Minotti, V., Tiseo, M., De Castro, J., 
Reed, N., Gislimberti, G., Singh, N., Stankovic, M., Öberg, K., Baudin, 
E. Efficacy and safety of pasireotide LAR or everolimus alone, or in 
combination in patients with advanced carcinoids (NET) of the 
lung/thymus: results from the randomized, phase 2 LUNA study. 
Lancet Oncol 18(12):1652–1664, 2017. 
Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretic, L., Seidal, D., 
Zander, T., Leenders, F., George, J., Muller, C., Dahmen, I., Pinther, B., 
Bosco, G., Konrad, K., Altmuller, J., Nurnberg, P., Achter, V., Lang, U., 
Schneider, P. M., Bogus, M., Soltermann, A., Brustugun, O. T., Helland, 
A., Solberg, S., Lund-Iversen, M., Ansen, S., Stoelben, E., Wright, G. M., 
Russell, P., Wainer, Z., Solomon, B., Field, J. K., Hyde, R., Davies, M. 
P., Heukamp, L. C., Petersen, I., Perner, S., Lovly, C., Cappuzzo, F., 
Travis, W. D., Wolf, J., Vingron, M., Brambilla, E., Haas, S. A., Buettner, 
R., Thomas, R. K. Frequent mutations in chromatin-remodelling genes 
in pulmonary carcinoids. Nat Commun 5:3518, 2014. 
FHRB web page, accessed in September 2019. http://www.fhrb.fi/. 
Filosso, P.L., Rena, O., Donati, G., Casadio, C., Ruffini, E., Papalia, E., Oliaro, 
A., Maggi, G.  Bronchial carcinoid tumors: surgical management and 
long-term outcome. J Thorac Cardiovasc Surg 123(2):303–309, 2002. 
Filosso, P. L., Guerrera, F., Evangelista, A., Welter, S., Thomas, P., Casado, P. 
M., Rendina, E. A., Venuta, F., Ampollini, L., Brunelli, A., Stella, F., 
Nosotti, M., Raveglia, F., Larocca, V., Rena, O., Margaritora, S., 
Ardissone, F., Travis, W. D., Sarkaria, I., Sagan, D. Prognostic model of 
survival for typical bronchial carcinoid tumours: analysis of 1109 
patients on behalf of the European Association of Thoracic Surgeons 
(ESTS) Neuroendocrine Tumours Working Group. Eur J Cardiothorac 
Surg 48(3):441–447, 2015. 
Filosso, P. L., Kidd, M., Roffinella, M., Lewczuk, A., Chung, K. M., Kolasinska-
Cwikla, A., Cwikla, J., Lowczak, A., Doboszynska, A., Malczewska, A., 
Catalano, M., Zunino, V., Boita, M., Arvat, E., Cristofori, R., Guerrera, 
F., Oliaro, A., Tesselaar, M., Buikhuisen, W., Kos-Kudla, B., Papotti, M., 
Bodei, L., Drozdov, I., Modlin, I. The utility of blood neuroendocrine 
gene transcript measurement in the diagnosis of bronchopulmonary 
neuroendocrine tumours and as a tool to evaluate surgical resection and 
disease progression. Eur J Cardiothorac Surg 53(3):631–639, 2018. 
FINBB web page, accessed in November 2019. https://finbb.fi/. 
Fink, G., Krelbaum, T., Yellin, A., Bendayan, D., Saute, M., Glazer, M., Kramer, 
M. R. Pulmonary carcinoid: presentation, diagnosis, and outcome in 
142 cases in Israel and review of 640 cases from the literature. Chest 
119(6):1647–1651, 2001. 






Gaskell, G., Gottweis, H., Starkbaum, J., Gerber, M. M., Broerse, J., Gottweis, 
U., Hobbs, A., Helen, I., Paschou, M., Snell, K., Soulier, A. Publics and 
biobanks: pan-European diversity and the challenge of responsible 
innovation. Eur J Hum Genet 21(1):14–20, 2013. 
Geramizadeh, B., Reza Foroutan, H., Shokripour, M., Reza Dehghanian, A. 
Pulmonary atypical carcinoid tumor in a 15-year-old girl: a case report 
and review of the literature. Rare Tumors 5(3):e45, 2013. 
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, 
V., Stephens, P. J., Daniels, G. A., Kurzrock, R. Tumor mutational 
burden as an independent predictor of response to immunotherapy in 
diverse cancers. Mol Cancer Ther 16(11):2598–2608, 2017. 
Gosain, R., Mukherjee, S., Yendamuri, S. S., Iyer, R. Management of typical 
and atypical pulmonary carcinoids based on different established 
guidelines. Cancers (Basel) 10(12):e510, 2018. 
Gosney, J. R., Sissons, M. C., Allibone, R. O. Neuroendocrine cell populations 
in normal human lungs: a quantitative study. Thorax 43(11):878–882, 
1988. 
Grizzle, W. E., Bledsoe, M. J., Al Diffalha, S., Otali, D., Sexton, K. C. The 
utilization of biospecimens: impact of the choice of biobanking model. 
Biopreserv Biobank 17(3):230–242, 2019. 
Grøndahl, V., Binderup, T., Langer, S. W., Petersen, R. H., Nielsen, K., Kjaer, 
A., Federspiel, B., Knigge. U. Characteristics of 252 patients with 
bronchopulmonary neuroendocrine tumours treated at the 
Copenhagen NET Centre of Excellence. Lung Cancer 132:141–149, 
2019. 
Gunther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, 
H. J., Lupp, A., Korbonits, M., Castano, J. P., Wester, H. J., Culler, M., 
Melmed, S., Schulz, S. International Union of Basic and Clinical 
Pharmacology. CV. Somatostatin receptors: structure, function, 
ligands, and new nomenclature. Pharmacol Rev 70(4):763–835, 2018. 
Gustafsson, B. I., Kidd, M., Chan, A., Malfertheiner, M. V., Modlin, I. M. 
Bronchopulmonary neuroendocrine tumors. Cancer 113(1):5–21, 
2008a. 
Gustafsson, B. I., Kidd, M., Modlin, I. M. Neuroendocrine tumors of the diffuse 
neuroendocrine system. Curr Opin Oncol 20(1):1–12, 2008b. 
Hallet, J., Law, C. H., Cukier, M., Saskin, R., Liu, N., Singh, S. Exploring the 
rising incidence of neuroendocrine tumors: a population-based 
analysis of epidemiology, metastatic presentation, and outcomes. 
Cancer 121(4):589–597, 2015. 
Halperin, D. M., Shen, C., Dasari, A., Xu, Y., Chu, Y., Zhou, S., Shih, Y. T., Yao, 
J. C. Frequency of carcinoid syndrome at neuroendocrine tumour 
diagnosis: a population-based study. Lancet Oncol 18(4):525–534, 
2017. 
Herde, R. F., Kokeny, K. E., Reddy, C. B., Akerley, W. L., Hu, N., Boltax, J. P., 
Hitchcock, Y. J. Primary Pulmonary Carcinoid Tumor: A Long-term 
Single Institution Experience. Am J Clin Oncol. 41(1):24–29, 2018. 
Hobbins, S., West, D., Peake, M., Beckett, P., Woolhouse, I. Patient 
characteristics, treatment and survival in pulmonary carcinoid 
tumours: an analysis from the UK National Lung Cancer Audit. BMJ 





Holub, P., Swertz, M., Reihs, R., van Enckevort, D., Muller, H., Litton, J. E. 
BBMRI-ERIC Directory: 515 biobanks with over 60 million biological 
samples. Biopreserv Biobank 14(6):559–562, 2016. 
Ianniello, A., Sansovini, M., Severi, S., Nicolini, S., Grana, C. M., Massri, K., 
Bongiovanni, A., Antonuzzo, L., Di Iorio, V., Sarnelli, A., Caroli, P., 
Monti, M., Scarpi, E., Paganelli, G. Peptide receptor radionuclide 
therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: 
prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. 
Eur J Nucl Med Mol Imaging 43(6):1040–1046, 2016. 
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., 
Mäcke, H.R., Rochlitz, C., Müller-Brand, J., Walter, M. A. Response, 
survival, and long-term toxicity after therapy with the radiolabeled 
somatostatin analogue [90Y-DOTA]-TOC in metastasized 
neuroendocrine cancers. J Clin Oncol 29(17):2416–2423, 2011. 
Jiang, Y., Hou, G., Cheng, W. The utility of 18F-FDG and 68Ga-DOTA-Peptide 
PET/CT in the evaluation of primary pulmonary carcinoid: a systematic 
review and meta-analysis. Medicine (Baltimore) 98(10):e14769, 2019. 
Kaemmerer, D., Specht, E., Sanger, J., Wirtz, R. M., Sayeg, M., Schulz, S., 
Lupp, A. Somatostatin receptors in bronchopulmonary neuroendocrine 
neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin 
Endocrinol Metab 100(3):831–840, 2015. 
Kanakis, G., Grimelius, L., Spathis, A., Tringidou, R., Rassidakis, G. Z., Oberg, 
K., Kaltsas, G., Tsolakis, A. V. Expression of somatostatin receptors 1-5 
and dopamine receptor 2 in lung carcinoids: implications for a 
therapeutic role. Neuroendocrinology 101(3):211–222, 2015. 
Kaprio, J. The Finnish Twin Cohort Study: an update. Twin Res Hum Genet 
16(1):157–162, 2013. 
Kasajima, A., Ishikawa, Y., Iwata, A., Steiger, K., Oka, N., Ishida, H., Sakurada, 
A., Suzuki, H., Kameya, T., Konukiewitz, B., Klöppel, G., Okada, Y., 
Sasano, H., Weichert, W. Inflammation and PD-L1 expression in 
pulmonary neuroendocrine tumors. Endocr Relat Cancer 25(3):339–
350, 2018. 
Knekt, P., Rissanen, H., Jarvinen, R., Heliovaara, M. Cohort Profile: The 
Finnish Mobile Clinic health surveys FMC, FMCF and MFS. Int J 
Epidemiol 46(6):1760–1761, 2017. 
Kneuertz, P. J., Kamel, M. K., Stiles, B. M., Lee, B. E., Rahouma, M., Harrison, 
S. W., Altorki, N. K., Port, J. L. Incidence and prognostic significance of 
carcinoid lymph node metastases. Ann Thorac Surg 106(4):981–988, 
2018. 
Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., 
Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., Kallioniemi, O. 
P. Tissue microarrays for high-throughput molecular profiling of tumor 
specimens. Nat Med 4(7):844–847, 1998. 
Koomen, B. M., Badrising, S. K., van den Heuvel, M. M., Willems, S. M. 
Comparability of PD-L1 immunohistochemistry assays for non-small 
cell lung cancer: a systematic review. Histopathology, 2019. 
Korner, M., Waser, B., Schonbrunn, A., Perren, A., Reubi, J. C. Somatostatin 
receptor subtype 2A immunohistochemistry using a new monoclonal 
antibody selects tumors suitable for in vivo somatostatin receptor 






Kornerup, L. S., Dam, G., Gronbaek, H. Survival and predictors of death for 
patients with bronchopulmonary carcinoid at a Danish tertiary NET 
centre. In Vivo 31(3):397–402, 2017. 
Korse, C. M., Taal, B. G., van Velthuysen, M. L., Visser, O. Incidence and 
survival of neuroendocrine tumours in the Netherlands according to 
histological grade: experience of two decades of cancer registry. Eur J 
Cancer 49(8):1975–1983, 2013. 
Kulke, M. H., Lenz, H. J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., 
Bergsland, E., Stuart, K., Tye, L., Huang, X., Li, J. Z., Baum, C. M., 
Fuchs, C. S. Activity of sunitinib in patients with advanced 
neuroendocrine tumors. J Clin Oncol 26(20):3403–3410, 2008. 
Kumar, V., Abbas, A. K., Aster, J. C. (editors). Robbins basic pathology, 10th 
edition. Elsevier Philadelphia, Pennsylvania, USA, 2018. Pages 495-
548. 
La Rosa, S., Imperatori, A., Giovanella, L., Garancini, S., Capella, C. Thyroid 
metastases from typical carcinoid of the lung differentiating between 
medullary thyroid carcinoma and neuroendocrine tumor metastasis to 
the thyroid. Thyroid 19(5):521–526, 2009. 
La Rosa, S., Chiaravalli, A.M., Placidi, C., Papanikolaou, N., Cerati, M., 
Capella, C. TTF1 expression in normal lung neuroendocrine cells and 
related tumors: immunohistochemical study comparing two different 
monoclonal antibodies. Virchows Arch 457(4):497–507, 2010. 
La Rosa, S., Volante, M., Uccella, S., Maragliano, R., Rapa, I., Rotolo, N., 
Inzani, F., Siciliani, A., Granone, P., Rindi, G., Dominioni, L., Capella, 
C., Papotti, M., Sessa, F., Imperatori, A. ACTH-producing tumorlets 
and carcinoids of the lung: clinico-pathologic study of 63 cases and 
review of the literature. Virchows Arch 475(5):587–597, 2019. 
Laddha, S. V., da Silva, E. M., Robzyk, K., Untch, B. R., Ke, H., Rekhtman, N., 
Poirier, J. T., Travis, W. D., Tang, L. H., Chan, C. S. Integrative genomic 
characterization identifies molecular subtypes of lung carcinoids. 
Cancer Res 79(17):4339–4347, 2019. 
Linnoila, R. I. Functional facets of the pulmonary neuroendocrine system. Lab 
Invest 86(5):425–444, 2006. 
Lococo, F., Margaritora, S., Cardillo, G., Filosso, P., Novellis, P., Rapicetta, C., 
Carleo, F., Bora, G., Cesario, A., Stefani, A., Rossi, G., Paci, M. 
Bronchopulmonary carcinoids causing Cushing Syndrome: results 
from a multicentric study suggesting a more aggressive behavior. 
Thorac Cardiovasc Surg 64(2):172–181, 2016. 
Lou, F., Sarkaria, I., Pietanza, C., Travis, W., Roh, M. S., Sica, G., Healy, D., 
Rusch, V., Huang, J. Recurrence of pulmonary carcinoid tumors after 
resection: implications for postoperative surveillance. Ann Thorac Surg 
96(4):1156–1162, 2013. 
Luke, C., Price, T., Townsend, A., Karapetis, C., Kotasek, D., Singhal, N., 
Tracey, E., Roder, D. Epidemiology of neuroendocrine cancers in an 









Malczewska, A., Oberg, K., Bodei, L., Aslanian, H., Lewczuk, A., Filosso, P. L., 
Wojcik-Giertuga, M., Rydel, M., Zielinska-Les, I., Walter, A., Suarez, A. 
L., Kolasinska-Cwikla, A., Roffinella, M., Jamidar, P., Ziora, D., 
Czyzewski, D., Kos-Kudla, B., Cwikla, J. NETest liquid biopsy is 
diagnostic of lung neuroendocrine tumors and identifies progressive 
disease. Neuroendocrinology 108(3):219–231, 2019a. 
Malczewska, A., Kidd, M., Matar, S., Kos-Kudla, B., Bodei, L., Oberg, K., 
Modlin, I. M. An assessment of circulating chromogranin A as a 
biomarker of bronchopulmonary neuroendocrine neoplasia: a 
systematic review and meta-analysis. Neuroendocrinology, 2019b. 
Marchevsky, A. M., Hendifar, A., Walts, A. E. The use of Ki-67 labeling index 
to grade pulmonary well-differentiated neuroendocrine neoplasms: 
current best evidence. Mod Pathol 31(10):1523–1531, 2018. 
Matoso, A., Singh, K. Jacob, R., Greaves, W. O., Tavares, R., Noble, L., Resnick, 
M. B., Delellis, R. A., Wang, L. J. Comparison of thyroid transcription 
factor-1 expression by 2 monoclonal antibodies in pulmonary and 
nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 
18(2):142–149, 2010. 
Maxwell, J. E., Howe, J. R. Imaging in neuroendocrine tumors: an update for 
the clinician. Int J Endocr Oncol 2(2):159–168, 2015. 
Mehnert, J. M., Rugo, H. S., O’Neil, B. H., A., S., Schellens, J. H. M., Cohen, R. 
B., Doi, T., Ott, P. A., Pishvaian, M. J., Puzanov, I., Aung, K. L., Hsu, C., 
Le Tourneau, C., Soria, J.-C., Elez, E., Tamura, K., Gould, M., Zhao, G., 
Stein, K., Piha-Paul, S. A. Pembrolizumab for patients with PD-L1–
positive advanced carcinoid or pancreatic neuroendocrine tumors: 
Results from the KEYNOTE-028 study. Ann Oncol 28 (Suppl 5):v142–
v157, 2017. 
Modlin, I. M., Lye, K. D., Kidd, M. A 5-decade analysis of 13,715 carcinoid 
tumors. Cancer 97(4):934–959, 2003. 
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., Kidd, M. 
Chromogranin A – biological function and clinical utility in neuro 
endocrine tumor disease. Ann Surg Oncol 17(9):2427–2443, 2010. 
Modlin, I. M., Drozdov, I., Kidd, M. The identification of gut neuroendocrine 
tumor disease by multiple synchronous transcript analysis in blood. 
PLoS One 8(5):e63364, 2013. 
Modlin, I. M., Kidd, M., Filosso, P. L., Roffinella, M., Lewczuk, A., Cwikla, J., 
Bodei, L., Kolasinska-Cwikla, A., Chung, K. M., Tesselaar, M. E., 
Drozdov, I. A. Molecular strategies in the management of 
bronchopulmonary and thymic neuroendocrine neoplasms. J Thorac 
Dis 9 (Suppl 15):1458–1473, 2017. 
Montuenga, L. M., Guembe, L., Burrell, M. A., Bodegas, M. E., Calvo, A., Sola, 
J. J., Sesma, P., Villaro, A. C. The diffuse endocrine system: from 
embryogenesis to carcinogenesis. Prog Histochem Cytochem 
38(2):155–272, 2003. 
Naalsund, A., Rostad, H., Strom, E. H., Lund, M. B., Strand, T. E. Carcinoid 
lung tumors – incidence, treatment and outcomes: a population-based 








Nassar, A. A., Jaroszewski, D. E., Helmers, R. A., Colby, T. V., Patel, B. M., 
Mookadam, F. Diffuse idiopathic pulmonary neuroendocrine cell 
hyperplasia: a systematic overview. Am J Respir Crit Care Med 
184(1):8–16, 2011. 
Okereke, I. C., Taber, A. M., Griffith, R. C., Ng, T. T. Outcomes after surgical 
resection of pulmonary carcinoid tumors. J Cardiothorac Surg 11:35, 
2016. 
Oliveira, A. M., Tazelaar, H. D., Wentzlaff, K. A., Kosugi, N. S., Hai, N., Benson, 
A., Miller, D. L., Yang, P. Familial pulmonary carcinoid tumors. Cancer 
91(11):2104–2109, 2001. 
Oronsky, B., Ma, P. C., Morgensztern, D., Carter, C. A. Nothing But NET: A 
review of neuroendocrine tumors and carcinomas. Neoplasia 
19(12):991–1002, 2017. 
Ott, P. A., Bang, Y. J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J. 
C., Rugo, H. S., Cohen, R. B., O'Neil, B. H., Mehnert, J. M., Lopez, J., 
Doi, T., van Brummelen, E. M. J., Cristescu, R., Yang, P., Emancipator, 
K., Stein, K., Ayers, M., Joe, A. K., Lunceford, J. K. T-cell-inflamed 
gene-expression profile, programmed death ligand 1 expression, and 
tumor mutational burden predict efficacy in patients treated with 
pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 
37(4):318–327, 2019. 
Papaxoinis, G., Lamarca, A., Quinn, A. M., Mansoor, W., Nonaka, D. Clinical 
and pathologic characteristics of pulmonary carcinoid tumors in central 
and peripheral locations. Endocr Pathol 29(3):259–268, 2018. 
Paragliola, R. M. & Salvatori, R. Novel Somatostatin Receptor Ligands 
Therapies for Acromegaly. Front Endocrinol 9:78, 2018. 
Pelosi, G., Bianchi, F., Dama, E., Simbolo, M., Mafficini, A., Sonzogni, A., 
Pilotto, S., Harari, S., Papotti, M., Volante, M., Fontanini, G., Mastracci, 
L., Albini, A., Bria, E., Calabrese, F., Scarpa, A. Most high-grade 
neuroendocrine tumours of the lung are likely to secondarily develop 
from pre-existing carcinoids: innovative findings skipping the current 
pathogenesis paradigm. Virchows Arch 472(4):567–577, 2018. 
Peltonen, L., Jalanko, A., Varilo, T. Molecular genetics of the Finnish disease 
heritage. Hum Mol Genet 8(10):1913–1923, 1999. 
Phan, A. T., Oberg, K., Choi, J., Harrison, L. H., Jr., Hassan, M. M., Strosberg, 
J. R., Krenning, E. P., Kocha, W., Woltering, E. A., Maples, W. J. 
NANETS consensus guideline for the diagnosis and management of 
neuroendocrine tumors: well-differentiated neuroendocrine tumors of 
the thorax (includes lung and thymus). Pancreas 39(6):784–798, 2010. 
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, 
T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., Peters, S. Metastatic 
non-small cell lung cancer: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann Oncol 30(5):863–870, 2019. 
Raivola, V., Snell, K., Helen, I., Partanen, J. Attitudes of blood donors to their 
sample and data donation for biobanking. Eur J Hum Genet 
27(11):1659–1667, 2019. 
Rea, F., Rizzardi, G., Zuin, A., Marulli, G., Nicotra, S., Bulf, R., Schiavon, M., 
Sartori, F. Outcome and surgical strategy in bronchial carcinoid 
tumors: single institution experience with 252 patients. Eur J 





Rekhtman, N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab 
Med 134(11):1628–1638, 2010. 
Remes, S. M., Tuominen, V. J., Helin, H., Isola, J., Arola, J. Grading of 
neuroendocrine tumors with Ki-67 requires high-quality assessment 
practices. Am J Surg Pathol 36(9):1359–1363, 2012. 
Reubi, J. C., Schonbrunn, A. Illuminating somatostatin analog action at 
neuroendocrine tumor receptors. Trends Pharmacol Sci 34(12):676–
688, 2013. 
Reynolds, J. P., Voss, J. S., Brankley, S. M., Caudill, J. M., Henry, M. R., 
Clayton, A. C., Halling, K. C., Nassar, A. Diagnostic accuracy of 
bronchial brush cytology and the added value of 
immunohistochemistry and fluorescence in situ hybridization of 
pulmonary neuroendocrine tumors. Cytojournal 11:32, 2014. 
Righi, L., Volante, M., Tavaglione, V., Bille, A., Daniele, L., Angusti, T., Inzani, 
F., Pelosi, G., Rindi, G., Papotti, M. Somatostatin receptor tissue 
distribution in lung neuroendocrine tumours: a clinicopathologic and 
immunohistochemical study of 218 'clinically aggressive' cases. Ann 
Oncol 21(3):548–555, 2010. 
Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., 
Brambilla, E., Busam, K. J., de Krijger, R. R., Dietel, M., El-Naggar, A. 
K., Fernandez-Cuesta, L., Kloppel, G., McCluggage, W. G., Moch, H., 
Ohgaki, H., Rakha, E. A., Reed, N. S., Rous, B. A., Sasano, H., Scarpa, 
A., Scoazec, J. Y., Travis, W. D., Tallini, G., Trouillas, J., van Krieken, J. 
H., Cree, I. A. A common classification framework for neuroendocrine 
neoplasms: an International Agency for Research on Cancer (IARC) 
and World Health Organization (WHO) expert consensus proposal. 
Mod Pathol 31(12):1770–1786, 2018. 
Rinke, A., Müller, H. H., Schade-Brittinger, C., Klose, K.J., Barth, P., Wied, M., 
Mayer, C., Aminossadati, B., Pape, U. F., Bläker, M., Harder, J., Arnold, 
C., Gress, T., Arnold, R.; PROMID Study Group. Placebo-controlled, 
double-blind, prospective, randomized study on the effect of octreotide 
LAR in the control of tumor growth in patients with metastatic 
neuroendocrine midgut tumors: a report from the PROMID Study 
Group. Clin Oncol 27(28):4656–4663, 2009.  
Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, 
E., Gress, T. M., Müller, H. H., Arnold, R.; PROMID Study Group. 
Placebo-controlled, double-blind, prospective, randomized study on 
the effect of octreotide LAR in the control of tumor growth in patients 
with metastatic neuroendocrine midgut tumors (PROMID): results of 
long-Term survival. Neuroendocrinology 104(1):26–32. 2017. 
Rojas, Y., Shi, Y. X., Zhang, W., Beierle, E. A., Doski, J. J., Goldfarb, M., Goldin, 
A. B., Gow, K. W., Langer, M., Vasudevan, S. A., Nuchtern, J. G. Primary 
malignant pulmonary tumors in children: a review of the national 
cancer data base. J Pediatr Surg 50(6):1004–1008, 2015. 
Rosai, J., Ackerman, L. V. (editors). Rosai and Ackerman's surgical pathology, 
10th edition. Mosby, Edinburgh, UK, 2011. Pages 348–436. 
Sachithanandan, N., Harle, R. A., Burgess, J. R. Bronchopulmonary carcinoid 







Schrevens, L., Vansteenkiste, J., Deneffe, G., De Leyn, P., Verbeken, E., 
Vandenberghe, T., Demedts, M. Clinical-radiological presentation and 
outcome of surgically treated pulmonary carcinoid tumours: a long-
term single institution experience. Lung Cancer 43(1):39–45, 2004. 
Shah, M. H., Halperin, D., Pillarisetty, V. G., Goldner, W. S., He, J., Reidy, D., 
Benson, A. B., Heslin, M. J., Saltz, L., Bergsland, E., Kalemkerian, G. P., 
Strosberg, J. R., Berlin, J. D., Kandeel, F., Sussman, C. A., Trikalinos, 
N. A., Chan, J., Kunz, P. L., Engstrom, P. F., Kuvshinoff, B. W., 
Whisenant, J., Fanta, P., Lieu, C., Wong, T., Giordano, T., Morris-Stiff, 
G., Halfdanarson, T. R., Burns, J. NCCN guidelines, Neuroendocrine 
and adrenal Tumors, Version 1.2019, March 5, 2019. Retrieved from 
https://www.nccn.org/professionals/physician_gls/. 
Shrager, J. B., Wright, C. D., Wain, J. C., Torchiana, D. F., Grillo, H. C., 
Mathisen, D. J. Bronchopulmonary carcinoid tumors associated with 
Cushing's syndrome: a more aggressive variant of typical carcinoid. J 
Thorac Cardiovasc Surg 114(3):367–375, 1997. 
Simbolo, M., Mafficini, A., Sikora, K. O., Fassan, M., Barbi, S., Corbo, V., 
Mastracci, L., Rusev, B., Grillo, F., Vicentini, C., Ferrara, R., Pilotto, S., 
Davini, F., Pelosi, G., Lawlor, R. T., Chilosi, M., Tortora, G., Bria, E., 
Fontanini, G., Volante, M., Scarpa, A. Lung neuroendocrine tumours: 
deep sequencing of the four World Health Organization histotypes 
reveals chromatin-remodelling genes as major players and a prognostic 
role for TERT, RB1, MEN1 and KMT2D. J Pathol 241(4):488–500, 
2017. 
Simbolo, M., Barbi, S., Fassan, M., Mafficini, A., Ali, G., Vicentini, C., 
Sperandio, N., Corbo, V., Rusev, B., Mastracci, L., Grillo, F., Pilotto, S., 
Pelosi, G., Pelliccioni, S., Lawlor, R. T., Tortora, G., Fontanini, G., 
Volante, M., Scarpa, A., Bria, E. Gene expression profiling of lung 
atypical carcinoids and large cell neuroendocrine carcinomas identifies 
three transcriptomic subtypes with specific genomic alterations. J 
Thorac Oncol 14(9):1651–1661, 2019. 
Skuladottir, H., Hirsch, F. R., Hansen, H. H., Olsen, J. H. Pulmonary 
neuroendocrine tumors: incidence and prognosis of histological 
subtypes. A population-based study in Denmark. Lung Cancer 
37(2):127–135, 2002. 
Snell, K. Mitä suomalaiset tietävät biopankeista? Lääkärilehti 36:1944–1945, 
2017. 
Snell, K., Tupasela, A. Miten suomalaiset suhtautuvat biopankkeihin? 
Duodecim 128:1685–1690, 2012. 
Strosberg, J. R., Mizuno, N., Doi, T., Grande, E., Delord, J.-P., Shapira-
Frommer, R., Bergsland, E. K., Shah, M. H., Fakih, M., Takahashi, S., 
Piha-Paul, S. A., O'Neil, B., Thomas, S., Lolkema, M. P., Wang, J. D., 
Ibrahim, N., Pruitt, S. K., Hadoux, J. Pembrolizumab treatment of 
advanced neuroendocrine tumors: Results from the phase II 
KEYNOTE-158 study. J Clin Oncol 37 (Suppl 4; abstr 190), 2019. 
Sullivan, I., Le Teuff, G., Guigay, J., Caramella, C., Berdelou, A., Leboulleux, 
S., Déandréis, D., Hadoux, J., Ducreux, M., Duvillard, P., Adam, J., 
Scoazec, J.Y., Baudin, E., Planchard, D. Antitumour activity of 
somatostatin analogues in sporadic, progressive, metastatic pulmonary 





Swarts, D. R., Claessen, S. M., Jonkers, Y. M., van Suylen, R. J., Dingemans, 
A. M., de Herder, W. W., de Krijger, R. R., Smit, E. F., Thunnissen, F. 
B., Seldenrijk, C. A., Vink, A., Perren, A., Ramaekers, F. C., Speel, E. J. 
Deletions of 11q22.3-q25 are associated with atypical lung carcinoids 
and poor clinical outcome. Am J Pathol 179(3):1129–1137, 2011. 
Swarts, D. R., Rudelius, M., Claessen, S. M., Cleutjens, J. P., Seidl, S., Volante, 
M., Ramaekers, F. C., Speel, E. J. Limited additive value of the Ki-67 
proliferative index on patient survival in World Health Organization-
classified pulmonary carcinoids. Histopathology 70(3):412–422, 2017. 
The Finnish Medical Society Duodecim. Current Care Guidelines, accessed in 
December 2019. https://www.kaypahoito.fi/suositukset 
Theodoropoulou, M., Stalla, G. K. Somatostatin receptors: from signaling to 
clinical practice. Front Neuroendocrinol 34(3):228–252, 2013. 
Thevenon, J., Bourredjem, A., Faivre, L., Cardot-Bauters, C., Calender, A., Le 
Bras, M., Giraud, S., Niccoli, P., Odou, M. F., Borson-Chazot, F., Barlier, 
A., Lombard-Bohas, C., Clauser, E., Tabarin, A., Pasmant, E., Chabre, 
O., Castermans, E., Ruszniewski, P., Bertherat, J., Delemer, B., 
Christin-Maitre, S., Beckers, A., Guilhem, I., Rohmer, V., Goichot, B., 
Caron, P., Baudin, E., Chanson, P., Groussin, L., Du Boullay, H., 
Weryha, G., Lecomte, P., Schillo, F., Bihan, H., Archambeaud, F., 
Kerlan, V., Bourcigaux, N., Kuhn, J. M., Verges, B., Rodier, M., Renard, 
M., Sadoul, J. L., Binquet, C., Goudet, P. Unraveling the intrafamilial 
correlations and heritability of tumor types in MEN1: a Groupe d'etude 
des Tumeurs Endocrines study. Eur J Endocrinol 173(6):819–826, 
2015. 
THL web page, accessed in December 2019. Terveydenhuollon kansalliset 
laatu-rekisterit. https://thl.fi/fi/web/sote-uudistus/arviointi-ja-
tietoikkuna/terveyden- huollon-kansalliset-laaturekisterit. 
THL Biobank web page, accessed in September 2019. 
https://thl.fi/en/web/thl-biobank. 
Travis, W. D., Brambilla, E., Burke, A. P., Marx, A., Nicholson, A. G. (editors). 
WHO classification of tumours of the lung, pleura, thymus and heart, 
4th edition. IARC, Lyon, France, 2015a. 
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., 
Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., 
Geisinger, K., Hirsch, F. R., Ishikawa, Y., Kerr, K. M., Noguchi, M., 
Pelosi, G., Powell, C. A., Tsao, M. S., Wistuba, I. The 2015 World Health 
Organization classification of lung tumors: impact of genetic, clinical 
and radiologic advances since the 2004 classification. J Thorac Oncol 
10(9):1243–1260, 2015b. 
Travis, W. D., Rush, W., Flieder, D. B., Falk, R., Fleming, M. V., Gal, A. A., 
Koss, M. N. Survival analysis of 200 pulmonary neuroendocrine tumors 
with clarification of criteria for atypical carcinoid and its separation 
from typical carcinoid. Am J Surg Pathol 22(8):934–944, 1998. 
Tsoukalas, N., Baxevanos, P., Fatorou, E. A., Tolia, M., Galanopoulos, M., 
Tsapakidis, K., Kyrgias, G., Toumpanakis, C., Kaltsas, G. Advances on 
systemic treatment for lung neuroendocrine neoplasms. Ann Transl 






Tsuta, K., Wistuba, II, Moran, C. A. Differential expression of somatostatin 
receptors 1-5 in neuroendocrine carcinoma of the lung. Pathol Res Pract 
208(8):470–474, 2012. 
Tuominen, V. J., Ruotoistenmaki, S., Viitanen, A., Jumppanen, M., Isola, J. 
ImmunoRatio: a publicly available web application for quantitative 
image analysis of estrogen receptor (ER), progesterone receptor (PR), 
and Ki-67. Breast Cancer Res 12(4):R56, 2010. 
U-CAN web page, accesssed in September 2019. http://www.u-can.uu.se/.  
UK Biobank web page, accessed in September 2019. 
https://www.ukbiobank.ac.uk/ 
Valvira. Biobank Registry. Accessed in September 2019. 
https://www.valvira.fi/terveydenhuolto/toimintaluvat/biopankit  
Van Lommel, A., Bolle, T., Fannes, W., Lauweryns, J. M. The pulmonary 
neuroendocrine system: the past decade. Arch Histol Cytol 62(1):1–16, 
1999. 
Vitale, G., Dicitore, A., Sciammarella, C., Di Molfetta, S., Rubino, M., Faggiano, 
A., Colao, A. Pasireotide in the treatment of neuroendocrine tumors: a 
review of the literature. Endocr Relat Cancer 25(6):351–364, 2018. 
Wang, H., Li, Z., Dong, B., Sun, W., Yang, X., Liu, R., Zhou, L., Huang, X., Jia, 
L., Lin, D. Prognostic significance of PD-L1 expression and CD8+ T cell 
infiltration in pulmonary neuroendocrine tumors. Diagn Pathol 
13(1):30, 2018. 
Wirtschafter, E., Walts, A. E., Liu, S. T., Marchevsky, A. M. Diffuse idiopathic 
pulmonary neuroendocrine cell hyperplasia of the lung (DIPNECH): 
current best evidence. Lung 193(5):659–667, 2015. 
Wolin, E. M. Advances in the diagnosis and management of well-differentiated 
and intermediate-differentiated neuroendocrine tumors of the lung. 
Chest 151(5):1141–1146, 2017. 
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, 
E. K., Fleming, J. B., Vauthey, J. N., Rashid, A., Evans, D. B. One 
hundred years after "carcinoid": epidemiology of and prognostic factors 
for neuroendocrine tumors in 35,825 cases in the United States. J Clin 
Oncol 26(18):3063–3072, 2008. 
Yao, J. C., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R., Van 
Cutsem, E., Singh, S., Fazio, N., He, W., Riester, M., Patel, P., Voi, M., 
Morrissey, M., Pavel, M. E., Kulke, M. H. Genomic profiling of NETs: a 
comprehensive analysis of the RADIANT trials. Endocr Relat Cancer 
26(4):391–403, 2019. 
Zarella, M. D., Bowman, D., Aeffner, F., Farahani, N., Xthona, A., Absar, S. F., 
Parwani, A., Bui, M., Hartman, D. J. A practical guide to whole slide 
imaging: a white paper from the digital pathology association. Arch 
Pathol Lab Med 143(2):222–234, 2019. 
Zlobec, I., Suter, G., Perren, A., Lugli, A. A next-generation tissue microarray 
(ngTMA) protocol for biomarker studies. J Vis Exp(91):51893, 2014. 
Öberg, K., Hellman, P., Ferolla, P., Papotti, M. Neuroendocrine bronchial and 
thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol 23 (Suppl 7):vii120–vii123, 2012. 
 
